60 results on '"Khaw, Peng"'
Search Results
2. List of Contributors
- Author
-
Amaya, Luis, primary, Ashworth, Jane L, additional, Avery, Robert A, additional, Bartram, Jack, additional, Beres, Shannon J, additional, Binenbaum, Gil, additional, Biousse, Valérie, additional, Birch, Eileen E, additional, Biswas, Susmito, additional, Black, Graeme C M, additional, Black, Joanna, additional, Bowman, Richard J C, additional, Bradbury, John A, additional, Brodsky, Michael C, additional, Brosnahan, Donal, additional, de Alba, Alejandra, additional, Camuglia, Jayne E, additional, Carden, Susan M, additional, Castano, Giovanni, additional, Casteels, Ingele, additional, Chung, Yvonne, additional, Clarke, Michael P, additional, Coats, David K, additional, Collin, Richard, additional, Crompton, John, additional, Cunningham, Emmett T, additional, Demer, Joseph L, additional, Dollfus, Hélène, additional, Dolman, Peter J, additional, Donahue, Sean P, additional, Edelsten, Clive, additional, Fielder, Alistair R, additional, FitzPatrick, David R., additional, Fulton, Anne B, additional, Gallie, Brenda L, additional, Geloneck, Megan, additional, Gilbert, Clare E, additional, Giligson, Christy, additional, Gole, Glen A, additional, Good, William V, additional, Grigg, John R B, additional, Grossniklaus, Hans, additional, Hamel, Patrick, additional, Handler, Sheryl M, additional, Hansen, Ronald M, additional, Heidary, Gena, additional, Hertle, Richard W, additional, Hildebrand, Göran Darius, additional, Holder, Graham E, additional, Hoyt, Creig S, additional, Hubbard, G Baker, additional, Hutchinson, Amy K, additional, Jain, Saurabh, additional, Jamieson, Robyn V, additional, Jensen, Hanne, additional, Kadom, Nadja, additional, Kekunnaya, Ramesh, additional, Kersten, Robert C, additional, Kestelyn, Philippe, additional, Keunen, Jan E E, additional, Khaw, Peng Tee, additional, Kim, Chong Ae, additional, Koopman, Jan, additional, Kraft, Stephen P, additional, Kushner, Burton J, additional, Lambert, Scott R, additional, LaRoche, G Robert, additional, Larsen, Dorte Ancher, additional, Lee, Andrew G, additional, Lee, Barry, additional, Lenhart, Phoebe, additional, Liasis, Alki, additional, Liu, Grant T, additional, Lloyd, Christopher, additional, Lyons, Christopher J, additional, Matsuba, Carey A, additional, MacEwen, Caroline J, additional, McNab, Alan A, additional, Mehta, Vaishali, additional, Michaelides, Michel, additional, Mojon, Daniel, additional, Ulrik, Hans, additional, Moore, Anthony T, additional, Morris, Andrew A M, additional, Newman, Nancy J, additional, Nischal, Ken K, additional, O'Colmain, Una, additional, O'Connor, Anna R, additional, O'Keefe, Michael, additional, Olitsky, Scott E, additional, Ospina, Luis H, additional, Oystreck, Darren T, additional, Papadopoulos, Maria, additional, Park, Sunju, additional, Paysse, Evelyn A, additional, Peragallo, Jason H, additional, Pereira, Erika Mota, additional, Pilling, Rachel F, additional, Pineles, Stacy, additional, Prajna, Venkatesh, additional, Proudlock, Frank Antony, additional, Puvanachandra, Narman, additional, Quinn, Anthony G, additional, Quinn, Graham E, additional, Rahi, Jugnoo S, additional, Repka, Michael X, additional, Robinson, Joshua, additional, Russell, Buddy, additional, de Sá, Luis Carlos Ferreira, additional, Sachdeva, Virender, additional, Salchow, Daniel J, additional, Scawn, Richard L, additional, Schalij-Delfos, Nicoline, additional, van Schooneveld, Mary J, additional, Self, Jay, additional, Sergouniotis, Panagiotis I, additional, Shields, Carol L, additional, Shields, Jerry A, additional, Sloper, John J, additional, Snead, Martin P, additional, Soliman, Sameh E, additional, Sullivan, Timothy John, additional, Summers, C Gail, additional, Tan, Kimberley, additional, Taylor, David S, additional, Thompson, Dorothy A, additional, Traboulsi, Elias I, additional, Tuft, Stephen J, additional, Uddin, Jimmy M, additional, Vijayalakshmi, Perumalsamy, additional, Watts, Patrick, additional, Weakley, David R, additional, and Wells, Jill Razor, additional
- Published
- 2017
- Full Text
- View/download PDF
3. Future Strategies
- Author
-
Khaw, Peng Tee, primary, Lockwood, Alastair, additional, Georgoulas, Stelios, additional, Dahlmann-Noor, Annegret H, additional, and Brocchini, Stephen, additional
- Published
- 2015
- Full Text
- View/download PDF
4. Primary congenital glaucoma
- Author
-
Ko, Fang, primary, Papadopoulos, Maria, additional, and Khaw, Peng T., additional
- Published
- 2015
- Full Text
- View/download PDF
5. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020
- Author
-
Burton, Matthew J, Ramke, Jacqueline, Marques, Ana Patricia, Bourne, Rupert RA, Congdon, Nathan, Jones, Iain, Ah Tong, Brandon AM, Arunga, Simon, Bachani, Damodar, Bascaran, Covadonga, Bastawrous, Andrew, Blanchet, Karl, Braithwaite, Tasanee, Buchan, John C, Cairns, John, Cama, Anasaini, Chagunda, Margarida, Chuluunkhuu, Chimgee, Cooper, Andrew, Crofts-Lawrence, Jessica, Dean, William H, Denniston, Alastair K, Ehrlich, Joshua R, Emerson, Paul M, Evans, Jennifer R, Frick, Kevin D, Friedman, David S, Furtado, João M, Gichangi, Michael M, Gichuhi, Stephen, Gilbert, Suzanne S, Gurung, Reeta, Habtamu, Esmael, Holland, Peter, Jonas, Jost B, Keane, Pearse A, Keay, Lisa, Khanna, Rohit C, Khaw, Peng Tee, Kuper, Hannah, Kyari, Fatima, Lansingh, Van C, Mactaggart, Islay, Mafwiri, Milka M, Mathenge, Wanjiku, McCormick, Ian, Morjaria, Priya, Mowatt, Lizette, Muirhead, Debbie, Murthy, Gudlavalleti VS, Mwangi, Nyawira, Patel, Daksha B, Peto, Tunde, Qureshi, Babar M, Salomão, Solange R, Sarah, Virginia, Shilio, Bernadetha R, Solomon, Anthony W, Swenor, Bonnielin K, Taylor, Hugh R, Wang, Ningli, Webson, Aubrey, West, Sheila K, Wong, Tien Yin, Wormald, Richard, Yasmin, Sumrana, Yusufu, Mayinuer, Silva, Juan Carlos, Resnikoff, Serge, Ravilla, Thulasiraj, Gilbert, Clare E, Foster, Allen, and Faal, Hannah B
- Published
- 2021
6. List of Contributors
- Author
-
Acharya, Nisha R, primary, Acheson, James F, additional, Adams, Gillian G W, additional, Ainsworth, John R, additional, de Alba Campomanes, Alejandra, additional, Allen, Louise E, additional, Ashworth, Jane Louise, additional, Aydin, Pinar, additional, Biousse, Valérie, additional, Biswas, Susmito, additional, Black, Graeme C M, additional, Black, Joanna, additional, Bosley, Thomas M, additional, Bowman, Richard J C, additional, Bradbury, John A, additional, Brodsky, Michael C, additional, Brookes, John L, additional, Brosnahan, Donal, additional, Buncic, J Raymond, additional, Camuglia, Jayne E, additional, Carden, Susan M, additional, Casteels, Ingele, additional, Cavuoto, Kara, additional, Chang, Wilma Y, additional, Clarke, Michael P, additional, Collin, J Richard O, additional, Crompton, John, additional, Cunningham, Emmett T, additional, Dahn, Kenneth K, additional, Day, Susan H, additional, Dollfus, Hélène, additional, Dutton, Gordon N, additional, Edelsten, Clive, additional, Elder, James, additional, Elston, John S, additional, Fielder, Alistair R, additional, Fitzpatrick, David R, additional, Fulton, Anne B, additional, Francis, Peter J, additional, Frederick, Douglas, additional, Funnell, Charlotte L, additional, Gallie, Brenda L, additional, Geloneck, Megan M, additional, Gilbert, Clare E, additional, Gole, Glen A, additional, Good, William V, additional, Gottlob, Irene, additional, Griffiths, Philip G, additional, Grigg, John R B, additional, Hammond, Christopher J, additional, Hanna, Nancy N, additional, Hall, Georgina, additional, Hansen, Ronald M, additional, Hatsukawa, Yoshikazu, additional, Henderson, Hugo W A, additional, Hertle, Richard W, additional, Hildebrand, Göran D, additional, Hingorani, Melanie, additional, Hodgkins, Peter, additional, Hollander, David A, additional, Holmström, Gerd S, additional, Holder, Graham E, additional, Hoyt, Creig, additional, Hunter, David G, additional, Jamieson, Robyn V, additional, Jan, James E, additional, Jain, Saurabh, additional, Jensen, Hanne, additional, Jolly, Rohit, additional, Kersten, Robert C, additional, Kestelyn, Phillippe, additional, Khaw, Peng T, additional, Kraft, Stephen P, additional, Kushner, Burton J, additional, Kyle, Robert A, additional, Lambert, Scott R, additional, LaRoche, G Robert, additional, Laws, David, additional, Lee, Andrew G, additional, Liasis, Alki, additional, Lloyd, Christopher, additional, Lyons, Christopher J, additional, MacEwen, Caroline J, additional, Mayer, D Luisa, additional, McKeown, Craig A, additional, McLeod, Stephen D, additional, Michaelides, Michel, additional, Miller, Joel M, additional, Miller, Neil R, additional, Mohamad, Nor Fadhilah, additional, Møller, Hans Ulrik, additional, Moore, Anthony T, additional, Morris, Andrew Alan Myles, additional, Morris, Robert, additional, Moskowitz, Anne, additional, Newman, Nancy J, additional, Nischal, Ken K, additional, Nishikawa, Hiroshi, additional, O’Keefe, Michael, additional, Papadopoulos, Maria, additional, Parulekar, Manoj V, additional, Parsa, Cameron F, additional, Pavesio, Carlos E, additional, Pau, Derrick C, additional, Paysse, Evelyn A, additional, Pereira, Erika Mota, additional, Pilling, Rachel Fiona, additional, Prajna, Venkatesh, additional, Proudlock, Frank A, additional, Quinn, Anthony, additional, Quinn, Graham E, additional, Rahi, Jugnoo S, additional, Rajamani, Muralidhar, additional, Reddy, M Ashwin, additional, Repka, Michael X, additional, Richard, Bruce, additional, Rootman, Jack, additional, Russell-Eggitt, Isabelle M, additional, Rutar, Tina, additional, de Sá, Luis Carlos Ferreira, additional, Sachdeva, Reecha, additional, Sagoo, Mandeep, additional, Salt, Alison, additional, Santiago, Alvina Pauline D, additional, Scawn, Richard L, additional, Scott, Alan B, additional, Self, Jay, additional, Sergouniotis, Panagiotis, additional, Shah, Ankoor S, additional, Shakoor, Akbar, additional, Shields, Carol L, additional, Shields, Jerry A, additional, Simmons, Ian, additional, Sloper, John J, additional, Snead, Martin P, additional, Souza-Dias, Carlos R, additional, Sowden, Jane C, additional, Speedwell, Lynne, additional, Stewart, Jay M, additional, Sugiyama, Yoshiko, additional, Sy, Aileen, additional, Tan, Naomi, additional, Taylor, David, additional, Taylor, Robert H, additional, Thompson, Dorothy A, additional, Timms, Chris, additional, Traboulsi, Elias I, additional, Tuft, Stephen John, additional, Tychsen, Lawrence, additional, Uddin, Jimmy M, additional, Verloes, Alain, additional, Vivian, Anthony J, additional, Watts, Patrick, additional, Weakley, David R, additional, Webb, David, additional, Wraith, James Edmond, additional, and Yu-Wai-Man, Patrick, additional
- Published
- 2013
- Full Text
- View/download PDF
7. Childhood glaucoma
- Author
-
Papadopoulos, Maria, primary, Brookes, John L, additional, and Khaw, Peng T, additional
- Published
- 2013
- Full Text
- View/download PDF
8. Wound-healing responses to glaucoma surgery
- Author
-
Georgoulas, Stelios, primary, Dahlmann-Noor, Annegret, additional, Brocchini, Stephen, additional, and Khaw, Peng Tee, additional
- Published
- 2010
- Full Text
- View/download PDF
9. List of Contributors
- Author
-
Adamis, Anthony P, primary, Adamus, Grazyna, additional, Albert, Daniel M, additional, Albertsmeyer, Ann-Christin, additional, Amerasinghe, Nishani, additional, Anderson, Michael G, additional, Atherton, Sally S, additional, Aung, Tin, additional, Bahn, Rebecca S, additional, Bardenstein, David Sander, additional, Barney, Neal P, additional, Beebe, David C, additional, Berman, Adrienne, additional, Bernstein, Audrey M, additional, Bhat, Pooja, additional, Borchman, Douglas, additional, Brocchini, Stephen, additional, Burgoyne, Claude, additional, Cabrera, Michelle Trager, additional, Cenedella, Richard J, additional, Chang, Jin-Hong, additional, Chappelow, Aimee, additional, Chauhan, Anuj, additional, Clark, Abbot F, additional, Cook, Ellen B, additional, Corrêa, Zélia M, additional, Cousins, Scott, additional, Cox, Gerald, additional, Croes, Scott Adam, additional, Csaky, Karl G, additional, Dahlmann-Noor, Annegret Hella, additional, Dana, Reza, additional, Danesh-Meyer, Helen, additional, Daniels, Julie T, additional, Dartt, Darlene A, additional, Dastjerdi, Mohammad H, additional, Daw, Nigel W, additional, Dawson, Daniel G, additional, Campomanes, Alejandra de Alba, additional, Demer, Joseph L, additional, Dintzis, Suzanne M, additional, Downs, J Crawford, additional, Edelhauser, Henry, additional, Ellenberg, David, additional, Elner, Victor, additional, Fisher, Steven K, additional, Folberg, Robert, additional, Foster, C Stephen, additional, Foulks, Gary N, additional, Fraunfelder, Frederick T, additional, Fraunfelder, Frederick W, additional, Fulton, Anne, additional, Gaster, Ronald, additional, Georgoulas, Stylianos, additional, Gilmore, Michael S, additional, Gipson, Ilene K, additional, Girard, Michaël J A, additional, Gordon, Lynn K, additional, Gottlob, Irene, additional, Gottsch, John D, additional, Graziano, Frank M, additional, Grossniklaus, Hans E, additional, Grzybowski, Deborah, additional, Guidry, Clyde, additional, Gupta, Neeru, additional, Gutmann, David H, additional, Gutti, Vinay, additional, Guy, John R, additional, Harbour, J William, additional, Hartnett, Mary Elizabeth, additional, Hayreh, Sohan S, additional, Heimer, Susan, additional, Hess, Robert, additional, Holekamp, Nancy M, additional, Huang, Suber S, additional, Iyengar, Sudha K, additional, Jackson, Allen T, additional, Johnson, L Alan, additional, Kador, Peter F, additional, Kahana, Alon, additional, Kardon, Randy, additional, Kenney, Maria Cristina, additional, Kern, Timothy Scott, additional, Khaw, Peng Tee, additional, Kim, Alice S, additional, Klassen, Henry, additional, Knepper, Paul, additional, Koretz, Jane F, additional, Kumaradas, Mirunalini, additional, Lass, Jonathan H, additional, Lederer, David, additional, Lesk, Mark, additional, Levin, Leonard A, additional, Lewis, Geoffrey P, additional, Li, Zhuqing, additional, Lin, Amy, additional, Linsenmeier, Robert A, additional, Listernick, Robert, additional, Lubow, Martin, additional, Maniotis, Andrew, additional, Massin, Pascale, additional, Matatall, Katie, additional, McCally, Russell L, additional, McLeod, Stephen D, additional, Memon, Muhammad, additional, Miller, Joan W, additional, Mircheff, Austin K, additional, Neitz, Jay, additional, Neitz, Maureen, additional, Nelson, Christine C, additional, Nickells, Robert, additional, Nussenblatt, Robert B, additional, O’Brien, Joan M, additional, Organisciak, Daniel T, additional, Paques, Michel, additional, Pelzel, Heather R, additional, Perera, Shamira, additional, Pierce, Eric A, additional, Pournaras, Jean, additional, Pribila, Jonathan T, additional, Proudlock, Frank A, additional, Qi, Xiaoping, additional, Rao, Narsing A, additional, Ritch, Robert, additional, Rizzo, Joseph F, additional, Roberts, Michael D, additional, Rosenbaum, James T, additional, Rouse, Barry, additional, Saban, Daniel R, additional, Sadun, Alfredo A, additional, Samadi, Abbas K, additional, Sarangi, Pranita, additional, Schachat, Andrew P, additional, Schechter, Joel E, additional, Schiefer, A Reagan, additional, Schlötzer-Schrehardt, Ursula, additional, Schmack, Ingo, additional, Schmetterer, Leopold, additional, Secker, Genevieve Aleta, additional, Sharma, Srilakshmi M, additional, Sharpe, James A, additional, Sheardown, Heather, additional, Shortt, Alex, additional, Shui, Ying-Bo, additional, Sigal, Ian, additional, Stahl, James L, additional, Steinert, Roger F, additional, Sundaram, Arun N E, additional, Sunness, Janet S, additional, Tagg, Nathan T, additional, Toffoli, Daniela, additional, Toth, Cynthia A, additional, Traboulsi, Elias I, additional, Tsai, James C, additional, Tucker, Budd, additional, Van Gelder, Russell N, additional, Völcker, Hans Eberhard, additional, von Bartheld, Christopher S, additional, Wang, Jianhua, additional, West-Mays, Judith, additional, Westerfeld, Corey B, additional, Wilson, Steven E, additional, de Medeiros, Fabricio Witzel, additional, Wu, Chih-Wei, additional, Yamada, Ai, additional, Yeh, Steven, additional, Yorio, Thomas, additional, Young, Michael J, additional, Young, Terri L, additional, Yücel, Yeni H, additional, Yue, Beatrice Y J T, additional, Zarbin, Marco A, additional, Zhang, Xinyu, additional, and Zheng, Mei, additional
- Published
- 2010
- Full Text
- View/download PDF
10. Antifibrotic Agents in Glaucoma Surgery
- Author
-
Khaw, Peng Tee, primary and Clarke, Jonathan, additional
- Published
- 2009
- Full Text
- View/download PDF
11. List of Contributors
- Author
-
Ahmed, Iqbal ike K., primary, Ahmed, Irma, additional, Ai, Everett, additional, Al-Ghoul, Ahmed, additional, Allen, David, additional, Alvi, Nishat P., additional, Anand, Rajiv, additional, Ang, Leonard P.-K., additional, Apple, David J., additional, Archer, Desmond B., additional, Arnold, Anthony C., additional, Arshinoff, Steve A., additional, Assil, Kerry K., additional, Atebara, Neal H., additional, Atluri, Harvinder K.S., additional, Augsburger, James J., additional, Aylward, G. William, additional, Azar, Dimitri T., additional, Baker, Brad J., additional, Balcer, Laura Joan, additional, Barnett, C.J., additional, Baumal, Caroline R., additional, Bearelly, Srilaxmi, additional, Benson, William E., additional, Berger, Steven Thomas, additional, Biswas, Jyotirmav, additional, Bolling, James P., additional, Bornfeld, Norbert, additional, Bose, Swaraj, additional, Bouchard, Charles S., additional, Boulton, Michael E., additional, Brandt, James D., additional, Brodsky, Michael C., additional, Brown, Kimberly Ellen, additional, Brown, Gary C., additional, Brown, Melissa M., additional, Budenz, Donald L., additional, Bui, Alex, additional, Burns, Stephen K., additional, Campolattaro, Brian N., additional, Cantor, Louis B., additional, Jr, Antonio Capone, additional, Carter, Keith D., additional, Chan, Chi-Chao, additional, Chang, Stanley, additional, Chao, Jennifer R., additional, Charonis, George C., additional, Chew, Paul T.K., additional, Ciardella, Antonio P., additional, Civan, Mortimer M., additional, Clark, Abbott F., additional, Clarke, Jonathan, additional, Contreras, Janice E., additional, Collin, J. Richard O., additional, Codère, François, additional, Corrêa, Zélia M., additional, Cowan, Claude L., additional, Craven, E. Randy, additional, Cruess, Alan F., additional, Custer, Phillip L., additional, Dahan, Elie, additional, Dai, Eric, additional, Damato, Bertil E., additional, Damji, Karim F., additional, Davidson, Richard S., additional, Davis, Elizabeth A., additional, Dhaliwal, Deepinder K., additional, Diamond, Gary R., additional, Do, Diana V., additional, Donahue, Sean P., additional, Dortzbach, Richard K., additional, Drenser, Kimberly A., additional, Duker, Jay S., additional, Dutton, Jonathan J., additional, Edgington, Bryan, additional, Eggers, Howard M., additional, Ehlers, William, additional, Engelbert, Michael, additional, Espandar, Ladan, additional, Evans, Monica, additional, Farjo, Ayad A., additional, Farjo, Qais Anastas, additional, Faucett, Donald C., additional, Feiz, Vahid, additional, Fine, I. Howard, additional, Fisher, Yale L., additional, Fishman, Gerald A., additional, Forster, David J., additional, Fox, Gregory M., additional, Freedman, Jeffrey, additional, Friedman, David S., additional, Friedman, Neil J., additional, Friedman, Deborah I., additional, Fu, Arthur D., additional, Fynn-Thompson, Nicoletta, additional, Ganatra, Jyotsom, additional, Gayre, Gregg S., additional, Gery, Igal, additional, Ghanem, Ramon C., additional, Giblin, Michael, additional, Gigantelli, James W., additional, Goldberg, Anna, additional, Goldberg, Robert A., additional, Goldberg, William, additional, Goldberg, Ivan, additional, Goldstein, Debra A., additional, Goldstein, Michael H., additional, Gonder, John R., additional, Green, Jeffrey P., additional, Greven, Craig M., additional, Gross, Nicole E., additional, Gross, Ronald L., additional, Grover, Sandeep, additional, Guercio, Jason R., additional, Gupta, Vishali, additional, Gupta, Amod, additional, Gurkan, Sevgi, additional, Guthoff, Rudolf E., additional, Hallak, Joelle, additional, Haller, Julia A., additional, Hamilton, Richard S., additional, Harbour, J. William, additional, Hardten, David R., additional, Harris, Alon, additional, Hedges Jr, Thomas R., additional, Heier, Jeffrey S., additional, Henderson, Polly A., additional, Herndon, Leon W., additional, Hitchings, Roger A., additional, Ho, Allen C., additional, Hoffman, Richard S., additional, Holz, Huck A., additional, Howard, Gene R., additional, Howes, Frank W., additional, Hsu, Jason, additional, Hurwitz, Jeffrey J., additional, Inomata, Hajime, additional, Ip, Michael, additional, Isaacs, Robert T., additional, Izak, Andrea M., additional, Jampel, Henry, additional, Jampol, Lee M., additional, Jiyamapa, Julia, additional, Johnson, Chris A., additional, Johnson, T. Mark, additional, Johnson, Mark W., additional, Jones, Nicholas, additional, Kahook, Malik, additional, Kanner, Elliott M., additional, Kapusta, Michael A., additional, Kardon, Randy, additional, Karp, Carol L., additional, Kass, Michael, additional, Katz, L. Jay, additional, Kaufman, Paul L., additional, Khan, Baseer, additional, Khaw, Peng Tee, additional, Kim, Gene, additional, Kimura, Alan E., additional, Kitzmann, Anna, additional, Klancnik, James M., additional, Koch, Douglas D., additional, Kohnen, Thomas, additional, Kojima, Takashi, additional, Kornmehl, Ernest W., additional, Kramarevsky, Natalia, additional, Labbe, Thad, additional, Lane, Stephen S., additional, Lavin, Patrick J.M., additional, Lawton, Andrew, additional, Lee, Paul P., additional, Leen, Martha Motuz, additional, Levinson, Ralph, additional, Lim, Ridia, additional, Lingua, Robert W., additional, Lipham, William J., additional, Lopez, Pedro F., additional, Lundstrom, Mats, additional, Magnante, Peter, additional, Mandava, Naresh, additional, Marak, George E., additional, Marmor, Michael F., additional, Marten, Lisa, additional, Mathura, Jeevan R., additional, Martidis, Adam, additional, Mattox, Cynthia, additional, McDermott, Mark L., additional, McLeod, Stephen D., additional, Mejico, Luis J., additional, Meyers, Sanford M., additional, Mieler, William F., additional, Migdal, Clive S., additional, Miller, David, additional, Miller, Russell, additional, Mimura, Tatsuya, additional, Mittra, Robert A., additional, Moorthy, Ramana S., additional, Morley, Michael G., additional, Morse, Lawrence S., additional, Moshirfar, Majid, additional, Moster, Mark L., additional, Nehls Rikkers, Sarah M., additional, Neff, Ann G., additional, Newlin, Anna C., additional, Noble, Kenneth G., additional, Noecker, Robert J., additional, Okada, Annabelle A., additional, Olson, Jeffrey L., additional, Opalinski, Yvonne A.V., additional, Packer, Mark, additional, Pandey, Suresh K., additional, Patel, Vivek Ravindra, additional, Pavesio, Carlos E., additional, Pineles, Stacy, additional, Piva, Alfio, additional, Piltz-Seymour, Jody, additional, Pollack, John S., additional, Prall, F. Ryan, additional, Price, Marianne O., additional, Price, Francis W., additional, Primack, Jonathan D., additional, Pruett, Ronald C., additional, Puliafito, Carmen A., additional, Pulido, Jose S., additional, Quiros, Peter A., additional, Ramulu, Pradeep, additional, Ramos-Esteban, Jerome C., additional, Rao, P. Kumar, additional, Rao, Narsing A., additional, Read, Russell W., additional, Rechtman, Ehud, additional, Regillo, Carl D., additional, Reichel, Elias, additional, Rhee, Douglas J., additional, Rhee, Steven S., additional, Rheinstrom, Stephen D., additional, Riedel, Patrick J., additional, Rikkers, Sarah M., additional, Robinson, Fiona O., additional, Rodriguez-Coleman, Hannah, additional, Rogers, Adam, additional, Roe, Richard, additional, Roh, Shiyoung, additional, Rosen, Emanuel S., additional, Rosenblatt, Brett, additional, Rosenfeld, Philip J., additional, Rubenstein, Jonathan B., additional, Rubin, Steven E., additional, Rubin, Richard M., additional, Rubsamen, Patrick E., additional, Saadati, Hossein G., additional, Sadun, Alfredo A., additional, Salim, Sarwat, additional, Salinas, Humberto, additional, Samuelson, Thomas W., additional, Sanborn, George E., additional, Sarmiento, Jerome S., additional, Scheufele Cleary, Tina A., additional, Schor, Paulo, additional, Schubert, Hermann D., additional, Schuman, Joel, additional, Schwab, Ivan R., additional, Schwartz, Gary S., additional, Scott, Clifford A., additional, Sebag, Jerry, additional, See, Jovina L.S., additional, Selkin, Robert P., additional, Shields, Bruce, additional, Shingleton, Bradford, additional, Sierra, Patricia B., additional, Sieving, Paul A., additional, Sivalingam, Arunan, additional, Small, Kent W., additional, Smiddy, William E., additional, Soong, Kaz, additional, Soukiasian, Sarkis, additional, Spaide, Richard F., additional, Spoor, Thomas C., additional, Stasi, Kalliopi, additional, Steel, David, additional, Stein, Joshua D., additional, Steinemann, Thomas L., additional, Suchecki, Jeanine, additional, Sugar, Joel, additional, Sugar, Alan, additional, Tan, J.C.H., additional, Tanenbaum, Myron, additional, Taravella, Michael J., additional, Tasman, William S., additional, Telander, David G., additional, Tennant, Matthew T.S., additional, Tessler, Howard H., additional, Thall, Edmond H., additional, Tingey, David P., additional, Tobaigy, Faisal M., additional, Truong, Steven, additional, Tsai, James C., additional, Tsai, Julie, additional, Tsiaras, William G., additional, Tu, Elmer Y., additional, Tucker, Nancy, additional, Tuli, Sonal S., additional, Valluri, Shailaja, additional, Vander, James F., additional, Vaughn, Gregory J., additional, Virasch, Vanee Val, additional, Wadia, Hormuz P., additional, Walker, Rebecca S., additional, Walton, David Sellers, additional, Wang, Li, additional, Wang, Frederick M., additional, Wang, Ming X., additional, Wang, Robert C., additional, Wax, Martin, additional, Weinberg, David V., additional, Weinstein, Joel M., additional, Weiter, John J., additional, Werner, Liliana, additional, Wevill, Mark T., additional, White, Paul F., additional, Wiggs, Janey L., additional, Wilkinson, Charles P., additional, Williams, Patrick D., additional, Williams, George A., additional, Wirostko, William J., additional, Wollstein, Gadi, additional, Yee, Robert D., additional, Young, Joshua A., additional, and Zamir, Ehud, additional
- Published
- 2009
- Full Text
- View/download PDF
12. PRIMARY CONGENITAL GLAUCOMA 743.20 (Primary Infantile Glaucoma, Buphthalmos)
- Author
-
Papadopoulos, Maria, primary and Khaw, Peng Tee, additional
- Published
- 2008
- Full Text
- View/download PDF
13. Tissue Repair and Regeneration
- Author
-
KHAW, PENG TEE, primary, GEORGOULAS, STELIOS, additional, DAHLMANN, ANNEGRET H., additional, MIRESKANDARI, KAMIAR, additional, BAILLY, MARYSE, additional, DANIELS, JULIE, additional, LIMB, ASTRID, additional, and BROCCHINI, STEPHEN, additional
- Published
- 2008
- Full Text
- View/download PDF
14. Glaucoma Filtration Surgery: Indications, Techniques, and Complications
- Author
-
Khaw, Peng Tee, primary, Chiang, Mark, additional, and Shah, Peter, additional
- Published
- 2008
- Full Text
- View/download PDF
15. List of Contributors
- Author
-
Abad, Juan-Carlos, primary, Abelson, Mark B, additional, Abramson, David H, additional, Acquadro, Martin A, additional, Adamis, Anthony P, additional, Adams, Wesley H, additional, Afshari, Natalie A, additional, Ai, Everett, additional, Aiello, Lloyd M, additional, Aiello, Lloyd P, additional, Akduman, Levent, additional, Albano, Marissa L, additional, Albert, Daniel M., additional, Alexandrou, Terry J, additional, Alfonso, Eduardo C, additional, Alié, Jorge L, additional, Alizadeh, Hassan, additional, Al Jadaan, Ibrahim A, additional, Al-Jastaneiah, Sabah, additional, Allen, Calliope E, additional, Allen, David, additional, Allen, Robert C, additional, Alm, Albert, additional, Al-Swailem, Samar, additional, Alt, Abigail K, additional, Altaweel, Michael M, additional, Anderson, Russell, additional, Andreoli, Christopher M, additional, Androudi, Sofia, additional, Ang, Leonard PK, additional, Anzaar, Fahd, additional, Apple, David J, additional, Arrigg, Claudia A, additional, Artal, Pablo, additional, Asbell, Penny, additional, Asdourian, George K, additional, Atebara, Neal, additional, Atmaca-Sonmez, Pelin, additional, Audo, Isabelle, additional, Auffarth, Gerd U, additional, Avery, Robin K, additional, Azar, Dimitri T, additional, Baker, Ann S, additional, Balles, Mark, additional, Barnes, Scott D, additional, Barnett, Donald M, additional, Barney, Neal P, additional, Barouch, Fina C, additional, Bartley, George B, additional, Barton, Jason JS, additional, Behlau, Irmgard, additional, Belda, Jose I, additional, Bennett, Jeffrey L, additional, Bennett, Timothy J, additional, Berdy, Gregg J, additional, Bernardino, Carlo Roberto, additional, Bernardino, Vitaliano, additional, Berson, Eliot L, additional, Bharadwaj, Amitabh, additional, Bhisitkul, Robert, additional, Bhui, Ravinder D, additional, Bilyk, Jurij, additional, Biousse, Valérie, additional, Bird, Alan C, additional, Blair, Norman Paul, additional, Blodi, Barbara A, additional, Blumenkranz, Mark S, additional, Boldt, H Culver, additional, Borchert, Mark S, additional, Borrillo, Luigi, additional, Borodic, Gary E, additional, Boruchoff, S Arthur, additional, Bose, Swaraj, additional, Boulton, Michael E, additional, Bowman, RW, additional, Bradley, Elizabeth A, additional, Brazitikos, Periklis D, additional, Breeze, Robert, additional, Bressler, Neil M, additional, Bressler, Susan B, additional, Brini, Alfred, additional, Budenz, Donald L, additional, Buffenn, Angela N, additional, Burk, Scott E, additional, Butrus, Salim, additional, Callanan, David, additional, Cameron, J Douglas, additional, Cantor, Louis B, additional, Cantore, William A, additional, Cantu-Dibildox, Jorge, additional, Casas, Victoria, additional, Casper, Miriam, additional, Casten, Robin J, additional, Catoira, Yara P, additional, Cavallerano, Jerry, additional, Chai, Samantha J, additional, Chalita, Maria R, additional, Chamberlain, Sherman M, additional, Chan, Audrey S, additional, Chan, Chi-Chao, additional, Chan, Paul, additional, Chapin, Matthew J, additional, Chapman, Karen L, additional, Chen, Eric, additional, Chen, Joe, additional, Chen, Julie A, additional, Chen, Teresa C, additional, Chen, Zhou, additional, Chévez-Barrios, Patricia, additional, Chew, Emily Y, additional, Chiang, Mark, additional, Chodosh, James, additional, Chong, Eva-Marie, additional, Chun, Denise, additional, Chylack, Leo T, additional, Ciardella, Antonio P, additional, Civan, Mortimer, additional, Clamen, Liane, additional, Clark, John I, additional, Cockerham, Glenn, additional, Cohen, Andre, additional, Cohen, Elisabeth J, additional, Colby, Kathryn A, additional, Coleman, Anne L, additional, Coleman, Hanna R, additional, Colin, Joseph, additional, Collier, J Michael, additional, Comer, Grant M, additional, Conlon, M Ronan, additional, Cooper, Kim E, additional, Corbett, James J, additional, Coma, Miguel C, additional, Cyrlin, Marshall N, additional, Dagi, Linda R, additional, Dahlgren, Matthew A, additional, Daley, Timothy J, additional, Da Mata, Andrea P, additional, Damato, Bertil, additional, D'Amico, Donald J, additional, Dana, Reza, additional, Danan-Husson, Aude, additional, Danesh-Meyer, Helen B, additional, Danis, Ronald P, additional, Darlington, Jason K, additional, Davidson, Stefanie L, additional, Davis, Janet L, additional, Davis, Elizabeth A, additional, de la Cruz, Jose J, additional, de la Garza, Adam G, additional, DeAngelis, Margaret M, additional, DeMartelaere, Sheri L, additional, Demer, Joseph L, additional, Dhaliwal, Avninder, additional, Dieckert, J Paul, additional, Do, Diana V, additional, Doane, Marshall G, additional, Dodds, Christopher, additional, Dohlman, Claes H, additional, Donati, Guy, additional, Donnenfeld, Eric D, additional, Drack, Arlene, additional, Dryja, Thaddeus P, additional, Dueker, David, additional, Duker, Jay S, additional, Dunbar, Jennifer A, additional, Dunn, James P, additional, Dupps, William J, additional, Durand, Marlene L, additional, Dutton, Jonathan J, additional, Eandi, Chiara M, additional, Edward, Deepak P, additional, Egan, Robert A, additional, Eichenbaum, David A, additional, Eklund, Susan E, additional, Engle, Elizabeth C, additional, Erickson, Kristine, additional, Esmaeli, Bita, additional, Fay, Aaron, additional, Feiner, Leonard, additional, Fekrat, Sharon, additional, Ferris, Frederick L, additional, Fine, Howard F, additional, Fletcher, Donald C, additional, Flikier, Paul, additional, Floyd, Richard P, additional, Flynn, Harry W, additional, Fong, Donald S, additional, Font, Ramon L, additional, Forbes, Brian JR, additional, Foroozan, Rod, additional, Foster, Bradley S, additional, Foster, C Stephen, additional, Foster, Jill A, additional, Foulks, Gary N, additional, Fountain, Tamara R, additional, Fox, Gregory M, additional, Freddo, Thomas F, additional, Freedman, Sharon F, additional, Freund, K Bailey, additional, Friberg, Thomas R, additional, Friedman, Alan H, additional, Friedman, David, additional, Friedman, Deborah I, additional, Friedman, Ephraim, additional, Fu, Arthur D, additional, Fulton, Anne B, additional, Galal, Ahmed, additional, Galetta, Steven, additional, Gallardo, Mark, additional, Gallie, Brenda, additional, Garner, Alec, additional, Garrity, James A, additional, Gatinel, Damien, additional, Gedde, Steven J, additional, Geist, Craig E, additional, Gerber, Steve, additional, Ghanem, Ramon C, additional, Gieser, Jon P, additional, Gilmore, Michael S, additional, Gimbel, Howard V, additional, Gipson, Ilene K, additional, Glover, Tyrone, additional, Goldberg, Robert A, additional, Goldenfeld, Mordechai, additional, Goldstein, Scott M, additional, Gomi, Cintia F, additional, Gong, Haiyan, additional, Gonzales, John A, additional, Goosey, John, additional, Gottlieb, Justin L, additional, Gould, Joshua, additional, Gragoudas, Evangelos S, additional, Granet, David B, additional, Greaney, Michael J, additional, Green, Daniel G, additional, Grehn, Franz, additional, Greiner, Jack V, additional, Greven, Craig M, additional, Griepentrog, Gregory J, additional, Groenewald, Carl, additional, Grosskreutz, Cynthia L, additional, Grover, Lori Latowski, additional, Gullapalli, Vamsi K, additional, Gulur, Padma, additional, Gunther, Jonathan, additional, Gupta, Manish, additional, Gupta, Mayank, additional, Guyer, David R, additional, Haivala, Darin R, additional, Haller, Julia A, additional, Halmagyi, GM, additional, Halperin, Lawrence S, additional, Hamdi, Islam M, additional, Hamilton, Steven R, additional, Hammersmith, Kristin M, additional, Han, Dennis P, additional, Hansen, Ronald M, additional, Harbour, J William, additional, Hariprasad, Seenu M, additional, Harissi-Dagher, Mona, additional, Hassan, Shirin E., additional, Hatton, Mark P, additional, Hawley, Pamela, additional, Hayashida, Yasutaka, additional, Heckenlively, John R, additional, Hedges, Thomas R, additional, Heggie, Alfred D, additional, Heher, Katrinka L, additional, Heier, Jeffrey S, additional, Hejtmancik, J Fielding, additional, Henderson, Bonnie A, additional, Hersh, Peter S, additional, Hidayat, Ahmed A, additional, Higginbotham, Eva Juliet, additional, Hirose, Tatsuo, additional, Ho, Allen C, additional, Ho, ThucAnh T, additional, Hogan, R Nick, additional, Holck, David E, additional, Holekamp, Nancy M, additional, Hovland, Peter G, additional, Hsu, Thomas C, additional, Hsu, William C, additional, Huang, Andrew JW, additional, Hughes, Mark S, additional, Hui, Jennifer, additional, Hunter, David G, additional, Huryn, Laryssa A, additional, Husain, Deeba, additional, Hyndiuk, Robert A, additional, Ip, Michael, additional, Jacobs, Brian J, additional, Jakobiec, Frederick A, additional, Jampol, Lee M, additional, Jensen, Harold G, additional, Ji, Fei, additional, Johnson, David L, additional, Johnson, Douglas H, additional, Johnson, Mark W, additional, Johnson, R Paul, additional, Johnson, Robert N, additional, Joos, Karen M, additional, Joyce, Nancy C, additional, Jumper, J Michael, additional, Jurkunas, Ula V., additional, Kahana, Alon, additional, Kahook, Malik Y, additional, Kanner, Elliott, additional, Kalwerisky, Kevin, additional, Kaplan, Henry J, additional, Karatza, Ekaterini C, additional, Kardon, Randy, additional, Katowitz, James A, additional, Katowitz, William R, additional, Kazlas, Melanie, additional, Keefe, Kelly S, additional, Kelley, Lara, additional, Kent, Charles J, additional, Kenyon, Kenneth R, additional, Khan, Bilal F, additional, Khan, Jemshed A, additional, Khan, Naheed W, additional, Khaw, Peng Tee, additional, Kherani, Femida, additional, Kim, Eva C, additional, Kim, Hee Joon, additional, Kim, Ivana K, additional, Kim, Jonathan W, additional, Kim, Rosa Y, additional, Kim, Stella K, additional, Kim, Tae-Im, additional, Klais, Christina M, additional, Klapper, Stephen R, additional, Klein, Barbara EK, additional, Kleinmann, Guy, additional, Klink, Thomas, additional, Klisovic, Dino D, additional, Klyce, Stephen D, additional, Kocaturk, Tolga, additional, Kohnen, Thomas, additional, Kojima, Takeshi, additional, Koller, Tobias, additional, Kostick, David A, additional, Kraut, Joel A, additional, Krishnan, Chandrasekharan, additional, Krueger, Ronald R, additional, Krug, Joseph H, additional, Krupsky, Sara, additional, Kuchtey, Rachel W, additional, Kurban, Ramsay S, additional, Kurz, Paul A, additional, Kuszak, JR, additional, Kwon, Young H, additional, Labbe, Thad A, additional, Lam, Deborah L, additional, Lamkin, Jeffrey C, additional, Lamping, Kathleen A, additional, Lane, Anne Marie, additional, Lane, Katherine A, additional, Lane, Keith J, additional, Lass, Jonathan H, additional, Lawrence, Mary G, additional, Lee, Andrew G, additional, Lee, Carol M, additional, Lee, Michael S, additional, Lee, Paul P, additional, Lee, William B, additional, Leibovitch, Igal, additional, Lemke, Bradley N, additional, Lemley, Craig A, additional, Leonardi, Andrea, additional, Lessell, Simmons, additional, Levin, Leonard A, additional, Levy-Clarke, Grace A, additional, Lew, Julie C, additional, Lewis, Craig, additional, Li, Wei, additional, Lim, Laurence S, additional, Lim, Lyndell L, additional, Lim, Wee-Kiak, additional, Liu, Grant T, additional, Loewenstein, John I, additional, Lott, McGregor N, additional, Lowry, Jonathan C, additional, Lyon, David B, additional, Lytle, Robert E, additional, MacCumber, Mathew, additional, Mackool, Bonnie T, additional, Madiwale, Nalini A, additional, Mah, Francis, additional, Mainster, Martin A, additional, Manning, Michael H, additional, Mansberger, Steven L, additional, Marc, Robert E, additional, Marchong, Mellone, additional, Marcus, Dennis M, additional, Mares, Julie A, additional, Marr, Brian P, additional, Martinez, Carlos E, additional, Massof, Robert W, additional, Matsumoto, Yukihiro, additional, Mattox, Cynthia, additional, Maus, Marlon, additional, McCabe, Cathleen M, additional, McCormick, Steven A, additional, McCrakken, Michael, additional, McCulley, James P, additional, McDermott, John A, additional, McDonald, H Richard, additional, McDonald, Marguerite B, additional, McDonnell, Peter J, additional, McGillivray, Robert, additional, McKeown, Craig A, additional, McLaughlin, James, additional, McMullen, W Wynn, additional, Melamed, Shlomo, additional, Meligonis, George, additional, Mendrinos, Efstratios, additional, Meyer, Dale R, additional, Meyerle, Catherine B, additional, Mieler, William F, additional, Migliori, Michael, additional, Mihm, Martin C, additional, Miller, Darlene, additional, Miller, David, additional, Miller, Joan W, additional, Miller, Neil R, additional, Mills, David M, additional, Mills, Monte D, additional, Milman, Tatyana, additional, Mogk, Lylas, additional, Mogk, Marja, additional, Monés, Jordi, additional, Montes-Micó, Robert, additional, Morse, Christie L, additional, Morton, Asa D, additional, Moskowitz, Anne, additional, Mukai, Shizuo, additional, Murphree, A Linn, additional, Murphy, Robert P, additional, Murray, Timothy G, additional, Murray, Philip I, additional, Nagao, Karina, additional, Neitz, Jay, additional, Neitz, Maureen, additional, Netland, Peter A, additional, Neufeld, Arthur H, additional, Newman, Nancy J, additional, Ng, Eugene WM, additional, Nguyen, Quan Dong, additional, Niederkorn, Jerry Y, additional, Noecker, Robert J, additional, Nussenblatt, Robert B, additional, O'Brien, Joan M, additional, O'Brien, Paul D, additional, O'Brien, Terrence P, additional, O'Day, Denis, additional, Olk, R Joseph, additional, Olsen, Karl R, additional, Onal, Sumru, additional, Ooi, Yen Hoong, additional, Opremcak, E Mitchel, additional, Ousler, George, additional, Ozment, Randall R, additional, Packer, Samuel, additional, Palmer, Millicent L, additional, Papaliodis, George N, additional, Park, DJ John, additional, Parke, David W, additional, Parsa, Cameron F, additional, Parsons, M Andrew, additional, Pasquale, Louis R, additional, Patel, Neha N, additional, Patel, Sayjal J, additional, Patrianakos, Thomas D, additional, Patrinely, James R, additional, Pavan-Langston, Deborah, additional, Peli, Eli, additional, Pepin, Susan M, additional, Perez, Victor L, additional, Pérez-Santonja, Juan J, additional, Perfect, John R, additional, Perry, Henry D, additional, Piatigorsky, Joram, additional, Pieramici, Dante, additional, Pierce, Eric A, additional, Pineda, Roberto, additional, Pless, Misha L, additional, Pomeranz, Howard D, additional, Pournaras, Constantin J, additional, Power, William, additional, Prakash, Manvi, additional, Prasad, Anita G, additional, Purvin, Valerie, additional, Quillen, David A, additional, Quinn, Graham E, additional, Rabena, Melvin D, additional, Rae, James L, additional, Raizman, Michael B, additional, Randazzo, Alessandro, additional, Rao, Narsing A, additional, Rapuano, Christopher J, additional, Reeves, Sherman W, additional, Regillo, Carl D, additional, Reichel, Elias, additional, Reinke, Martin H, additional, Rhee, Douglas, additional, Richter, Claudia U, additional, Rizzo, Joseph F, additional, Robb, Richard M, additional, Roden, Anja C, additional, Rodgers, I Rand, additional, Rodrigues, Merlyn M, additional, Ron, Yonina, additional, Rose, Geoffrey E, additional, Rosen, Emanuel S, additional, Rosenbaum, James T, additional, Rosenthal, Perry, additional, Rouse, Strutha C, additional, Rovner, Barry W, additional, Rozanowska, Malgorzata, additional, Rubin, Michael P, additional, Rubin, Peter AD, additional, Rumelt, Shimon, additional, Rustgi, Anil K, additional, Rutar, Tina, additional, Ruttum, Mark S, additional, Rutzen, Allan R, additional, Ryan, Edward T, additional, Sadun, Alfredo A, additional, Sahel, José-Alain, additional, Saligan, Leorey, additional, Salim, Sarwat, additional, Salmon, John F, additional, Salomão, Diva R, additional, Sami, David, additional, Sandberg, Michael A, additional, Sangwan, Virender S, additional, Saornil, Maria A, additional, Sassani, Joseph W, additional, Sayegh, Rony R, additional, Schachat, Andrew P, additional, Schell, Wiley A, additional, Schefler, Amy C, additional, Scheufele, Tina, additional, Schiedler, Vivian, additional, Schneider, Gretchen, additional, Schroeder, Alison, additional, Schuchard, Ronald A, additional, Schuman, Joel S, additional, Schwab, Ivan R, additional, Scott, Adrienne, additional, Scott, Ingrid U, additional, Sears, Marvin L, additional, Seddon, Johanna M, additional, Seiler, Theo, additional, Selkin, Robert P, additional, Semba, Richard D, additional, Serbanescu, Irina, additional, Sexton, Briar, additional, Shaarawy, Tarek M, additional, Shah, Peter, additional, Shapiro, Aron, additional, Sharma, Savitri, additional, Shein, Jean, additional, Shetlar, Debra J, additional, Shields, M Bruce, additional, Shields, Carol L, additional, Shields, Jerry A, additional, Shingleton, Bradford J, additional, Shore, John W, additional, Shuba, Lesya M, additional, Simon, Guy J Ben, additional, Simmons, Richard J, additional, Simpson, Michael, additional, Singh, Arun D, additional, Singh, Omah S, additional, Sisley, Karen, additional, Sit, Arthur J, additional, Smerdon, David, additional, Smiddy, William E, additional, Smith, Ronald E, additional, Smith, Terry J, additional, Snebold, Neal G, additional, Sobrin, Lucia, additional, Sorenson, John A, additional, Soukiasian, Sarkis H, additional, Spaeth, George L, additional, Spaide, Richard F, additional, Srivastava, Monika, additional, Srivastava, Sunil K, additional, Stangos, Alexandros N, additional, Starck, Tomy, additional, Stark, Walter J, additional, Stein, Joshua D, additional, Steinert, Roger F, additional, Strauss, Leon, additional, Streeten, Barbara W, additional, Streilein, J Wayne, additional, Strong, James D, additional, Sugino, Ilene K, additional, Suhler, Eric B, additional, Sullivan, Timothy J, additional, Sun, Jennifer K, additional, Sunness, Janet S, additional, Sutula, Francis C, additional, Syed, Nasreen A, additional, Ta, Christopher N, additional, Takei, Hidehiro, additional, Talamo, Jonathan H, additional, Tamesis, Richard R, additional, Tamhankar, Madhura, additional, Tarbet, Kristen J, additional, Tarver-Carr, Michelle, additional, Terry, Mark A, additional, Thomas, Joseph M, additional, Thompson, Vance, additional, Thorne, Jennifer E, additional, Thurtell, Matthew J, additional, Tingey, David P, additional, To, King W, additional, Tobaigy, Faisal M, additional, Tolentino, Michael J, additional, Tong, Melissa G, additional, Torkildsen, Gail, additional, Toth, Cynthia A, additional, Traboulsi, Elias I, additional, Trucksis, Michele, additional, Tsai, James C, additional, Tsai, Julie H, additional, Tse, David T, additional, Tseng, Scheffer CG, additional, Tu, Elmer Y, additional, Udell, Ira J, additional, Valenzuela, Alejandra A, additional, Van Gelder, Russell N, additional, Van Stavern, Gregory P, additional, Vander Veen, Deborah K, additional, Vavvas, Demetrios, additional, Verity, David H, additional, Vinciguerra, Paolo, additional, Vinger, Paul F, additional, Volpe, Nicholas J, additional, Wackernagel, Werner, additional, Wadhwa, Sonal Desai, additional, Wagoner, Michael D, additional, Waheed, Nadia K, additional, Walton, David S, additional, Wand, Martin, additional, Wang, Jie Jin, additional, Warden, Scott M, additional, Webb, Lennox, additional, Weber, David, additional, Wee, Daniel, additional, Westerfeld, Corey B, additional, Westfall, Christopher T, additional, Whitcup, Scott M, additional, White, Valerie A, additional, White, William L, additional, Wickens, Jason, additional, Wiggs, Janey L, additional, Wilensky, Jacob T, additional, Wilkinson, Charles P, additional, Williams, Patrick D, additional, Wilson, David J, additional, Wilson, M Roy, additional, Wilson, Steven E, additional, Winokur, Jules, additional, Wirostko, William J, additional, Wollstein, Gadi, additional, Wong, Albert Chak Ming, additional, Wong, Tien Y, additional, Woog, John J, additional, Wride, Michael, additional, Wu, Carolyn S, additional, WuDunn, Darrell, additional, Yang, Jean, additional, Yannuzzi, Lawrence A, additional, Yaremchuk, Michael J, additional, Yeatts, R Patrick, additional, Yee, Richard W, additional, Yeh, Steven, additional, Young, Lucy HY, additional, Yu, Jenny Y, additional, Yue, Beatrice YJT, additional, Zacks, Charles M, additional, Zagelbaum, Bruce M, additional, Zamani, Maryam, additional, Zarbin, Marco, additional, Zografos, Leonidas, additional, and Zoumalan, Christopher I, additional
- Published
- 2008
- Full Text
- View/download PDF
16. Contributors
- Author
-
Bailly, Maryse, primary, Barney, Neal P., additional, Beebe, David C., additional, Bennett, Jean, additional, Brandt, Curtis R., additional, Brocchini, Stephen, additional, Caprioli, Joseph, additional, Chader, Gerald J., additional, Chen, Jing, additional, Clark, Abbot F., additional, Coca-Prados, Miguel, additional, Dahlmann, Annegret H., additional, Dana, M. Reza, additional, Daniels, Julie, additional, Del Priore, Lucian V., additional, Foulks, Gary N., additional, Gabelt, B'ann T., additional, Georgoulas, Stelios, additional, Kahook, Malik Y., additional, Kaplan, Henry J., additional, Kaufman, Paul L., additional, Khaw, Peng Tee, additional, Limb, Astrid, additional, Liu, Xuyang, additional, Medeiros, Fabricio W., additional, Mireskandari, Kamiar, additional, Niederkorn, Jerry Y., additional, Pang, Iok-Hou, additional, Piri, Natik, additional, Prasanna, Ganesh, additional, Rasmussen, Carol A., additional, Schaal, Shlomit, additional, Schlech, Barry A., additional, Schuman, Joel S., additional, Shui, Ying-Bo, additional, Smith, Lois E.H., additional, Stone, Richard A., additional, Tezel, Tongalp H., additional, van Gelder, Russell N., additional, Wax, Martin B., additional, Weiner, Alan L., additional, Wilson, Steven E., additional, Wordinger, Robert J., additional, Yanni, John M., additional, and Yorio, Thomas, additional
- Published
- 2008
- Full Text
- View/download PDF
17. Modulation of wound healing during and after glaucoma surgery
- Author
-
Georgoulas, Stelios, primary, Dahlmann-Noor, Annegret, additional, Brocchini, Stephen, additional, and Khaw, Peng Tee, additional
- Published
- 2008
- Full Text
- View/download PDF
18. Contributors
- Author
-
Acheson, James F., primary, Adams, G.G.W., additional, Amure, Larry, additional, Andrews, Richard, additional, Barton, Keith, additional, Bates, Adam, additional, Bird, Alan C., additional, Bloom, Jill, additional, Brookes, John, additional, Burton, Ben J.L., additional, Collin, Richard O., additional, Cook, Helen L., additional, Cunningham, Carol, additional, Cruz, Lyndon Da, additional, Dandekar, Samantha, additional, Dart, John K.G., additional, Egan, Catherine, additional, Ehrlich, Daniel P., additional, El-Amir, Ahmed N., additional, Foster, Paul J., additional, Franks, Wendy, additional, Gartry, David, additional, Garway-Heath, Ted, additional, Goh, David, additional, Gregor, Zdenek J., additional, Hardy, Thomas, additional, Hart, Richard H., additional, Henderson, Hugo, additional, Holder, Graham E., additional, Hungerford, John L., additional, Jackson, Timothy L., additional, Jain, Rajni, additional, Khaw, Peng T., additional, Lightman, Susan L., additional, Lim, Natasha, additional, Macalister, Graham, additional, Manzouri, Bita, additional, Martin, Keith, additional, McCarry, Bernadette, additional, McElhatton, Patricia, additional, Merriman, Michael, additional, Michaelides, Michel, additional, Mohammed, Moin, additional, Moore, A.T., additional, Mruthyunjaya, Prithvi, additional, Murdoch, Ian, additional, Nambiar, Anil, additional, Nolan, Winifred, additional, Okhravi, Narciss, additional, Pavesio, Carlos E., additional, Plant, Gordon T., additional, Papadopoulos, Maria, additional, Rai, Poornima, additional, Rajan, Madhavan, additional, Ramchandani, Mahesh, additional, Ramkissoon, Yashin, additional, Restori, Marie, additional, Roberson, Geoff, additional, Rose, Geoffrey E., additional, Sehmi, Kulwant, additional, Siriwardena, Dilani, additional, Sloper, John, additional, Smith, Guy T., additional, Sullivan, Paul M., additional, Timms, Chris, additional, Tufail, Adnan, additional, Uddin, Jimmy, additional, Verity, David H., additional, and Viswanathan, Ananth, additional
- Published
- 2008
- Full Text
- View/download PDF
19. CONTRIBUTORS
- Author
-
Abbott, Richard L., primary, Afshari, Natalie A., additional, Agrawal, Jaya, additional, Agrawal, Shishir, additional, Agrawal, Trilok P., additional, Akduman, Levent, additional, Akpek, Esen K., additional, Al-Sayyed, Amal, additional, Albini, Thomas A., additional, Alcorn, Deborah M., additional, Alwitry, Amar, additional, Amzel, Anouk, additional, Anderson, Nicole J., additional, Ansari, Ejaz A., additional, Antoszyk, Andrew, additional, Antoszyk, James H., additional, Aquavella, James V., additional, Arain, Sumaira A., additional, Arévalo, J. Fernando, additional, Arunagiri, Guruswami, additional, Arzabe, Carlos W., additional, Atchaneeyasakul, La-ongsri, additional, Atilla, Huban, additional, Aykan, Ümit, additional, Ayres, Brandon D., additional, Barbón, Juan J., additional, Bailey, Kristi, additional, Baloh, Frank G., additional, Barequet, Irina S., additional, Barkhuizen, André, additional, Bearn, Michael A., additional, Belfort, Rubens, additional, Bellows, A. Robert, additional, Berrocal, Audina M., additional, Bettink-Remeijer, Marijke Wefers, additional, Bhandari, Anuja, additional, Bhatti, M. Tariq, additional, Blumenkranz, Mark S., additional, Boboridis, Kostas G., additional, Bolling, James P., additional, Boniuk, Vivien, additional, Botelho, Paul Jorge, additional, Brazis, Paul W., additional, Bremner, Fion D., additional, Buckley, Edward G., additional, Bullock, John D., additional, Bushley, David Matthew, additional, Caldeira, Jorge Alberto F., additional, Carricajo, Anne, additional, Cavallini, Gian Maria, additional, Chan, Matilda Frances, additional, Chandler, Damon B., additional, Channa, H., additional, Char, Devron H., additional, Charles, Steve, additional, Chen, Teresa C., additional, Ching, Steven S.T., additional, Chiquet, Christophe, additional, Hyunchul, Phillip, additional, Chou, Timothy Y., additional, Christiansen, Stephen P., additional, Chung, Kelly D., additional, Cioffi, George A., additional, Clarke, Michael P., additional, Coats, David K., additional, Cohen, Elisabeth J., additional, Conway, R. Max, additional, Creuzot-Garcher, Catherine, additional, Cunningham, Emmett T., additional, Curtis, Theodore H., additional, Dailey, Roger A., additional, Davis, Richard M., additional, Cock, Romain De, additional, de Faber, Jan-Tjeerd H.N., additional, de la Mano, Daniel, additional, Dekkers, Nick W.H.M., additional, Monte, Monte Anthony Del, additional, Rocca, David A. Della, additional, Rocca, Robert C. Della, additional, Dhaliwal, Deepinder K., additional, Do, Diana V., additional, Dolman, Peter J., additional, Donahue, Sean P., additional, Donnenfeld, Eric D., additional, Duguid, Graham, additional, Duker, Jay S., additional, Dunn, James P., additional, Dunn, Steven P., additional, Duong, Hon-Vu Q., additional, Egan, Robert A., additional, Eichler, Michael D., additional, El-Dairi, Mays, additional, Ellis, Forrest J., additional, Emerson, Geoffrey, additional, Emerson, M. Vaughn, additional, Enyedi, Laura B., additional, Evans, Teodoro, additional, Falardeau, Julie, additional, Faris, Bishara M., additional, Feitl, Marianne E., additional, Felton, Warren L., additional, Feman, Stephen S., additional, ffytche, Timothy J, additional, Flaxel, Christina J., additional, Foroozan, Rod, additional, Foster, Allen, additional, Fraunfelder, Frederick T., additional, Fraunfelder, Frederick W., additional, Freeman, H. Mackenzie, additional, Friedlaender, Mitchell H., additional, Frohman, Larry P., additional, Fung, Wayne E., additional, Gain, Philippe, additional, Gaitan, Jaime R., additional, Gancher, Stephen, additional, Gard, Tim, additional, Gattey, Devin M., additional, Gehlbach, Peter L., additional, Ghajarnia, Mehdi, additional, Ghanem, Vinícius Coral, additional, Ghosh, Amit Kumar, additional, Ghosh, Chandak, additional, Giegengack, Matthew, additional, Gladstone, Geoffrey, additional, Gold, Daniel H., additional, Golub, Richard L., additional, Gombos, Dan S., additional, Gombos, George M., additional, Good, William V., additional, Goodman, Shawn, additional, Gottsch, John D., additional, Goverdhan, Srinivas, additional, Grimson, Baird S., additional, Güemes, Adolfo, additional, Guerra, Roberto, additional, Haller, Julia A., additional, Hammersmith, Kristin M., additional, Handelman, Irvin L., additional, Hargrove, Roderick N., additional, Harney, Michael S., additional, Harper, Richard A., additional, Hatt, Sarah R., additional, Hawkins, Barbara S., additional, Hayreh, Sohan S., additional, Heiligenhaus, Arnd, additional, Heinz, Carsten, additional, Herndon, Leon W., additional, Hickman, Simon J., additional, Hirano, Koji, additional, Holland, Edward J., additional, Holland, Gary N., additional, Holz, Eric R., additional, Hommura, Sachiko, additional, Horn, Jeffrey D., additional, Hornick, Richard B., additional, Hoskins, H. Dunbar, additional, Hung, James W., additional, Hunter, Brian A., additional, Hunter, Krista A., additional, Hunyor, Alex P., additional, Hurwitz, Brian, additional, Hwang, Thomas S., additional, Hyndiuk, Robert A., additional, Ilhan-Sarac, Ozge, additional, Ing, Edsel, additional, Ino-ue, Masanori, additional, Isada, Carlos M., additional, Iturriaga, Saylin, additional, Iuorno, Joseph D., additional, Iwach, Andrew G., additional, Iyer, Mohan N., additional, Izquierdo, Natalio J., additional, Jampol, Lee M., additional, Johnston, Suzanne, additional, Kadayifçilar, Sibel, additional, Kaden, Ian H., additional, Kaimbo, Dieudonne Kaimbo Wa, additional, Kapur, Rashmis, additional, Kastl, Peter R., additional, Katsavounidou, Garyfallia, additional, Kazerouni, Ayat, additional, Kazim, Michael, additional, Kedhar, Sanjay R., additional, Keech, Ronald V., additional, Kersten, Robert C., additional, Keys, Marshall P., additional, Khanna, Sangeeta, additional, Khaw, Peng Tee, additional, Kinyoun, James L., additional, Kirwan, Caitriona, additional, Kivelä, Tero, additional, Klein, Michael L., additional, Klotz, Stephen A., additional, Ko, John, additional, Kowalski, Regis P., additional, Krachmer, Jay H., additional, Krupin, Theodore, additional, Kuhn, Ferenc, additional, Kulkarni, Abhaya Vivek, additional, Kwun, Robert C., additional, Laibson, Peter R., additional, Lakhanpal, Rohit R., additional, Lam, Byron L., additional, Lamer, Laurent, additional, Lawlor, David P., additional, Lawton, Andrew W., additional, Leahey, Alan B., additional, LeBoyer, Russell, additional, Lee, Andrew G., additional, Lee, Wen-Hsiang, additional, Lee, William Barry, additional, Lehman, Sharon S., additional, Leibowitz, Howard M., additional, Leong, James, additional, Levin, Alex V., additional, Levin, Leonard A., additional, Levine, Mark R., additional, Levy, Norman S., additional, Liesegang, Thomas J., additional, Lim, Lyndell L., additional, Lin, Linda H., additional, Lisman, Richard D., additional, Litoff, David, additional, Liu, James C., additional, Loft, Evan, additional, Lubritz, Ronald R., additional, Mabey, David C.W., additional, Mackie, Ian A., additional, Maguluri, Srilakshmi, additional, Maliki, M., additional, Mamalis, Nick, additional, Mannis, Mark J., additional, Mansberger, Steven L., additional, Mansour, Ahmad M., additional, Marcon, Alexandre S., additional, Marcon, Italo M., additional, Marsh, Peter B., additional, Mather, Rookaya, additional, Mathers, William D., additional, Saari, K. Matti, additional, Mawn, Louise A., additional, McAllum, Penny J., additional, McCallum, Rex M., additional, McCluskey, Peter, additional, McCormick, Gregory J., additional, McCormick, Steven A., additional, McCulley, James P., additional, McHenry, John G., additional, McNab, Alan A., additional, Mee, Jared J., additional, Meier, Douglas L., additional, Meisler, David M., additional, Merin, Saul C., additional, Meyer, Dale R., additional, Meyer, Roger F., additional, Michels, Kevin S., additional, Milman, Tatyana, additional, Mintz, Roni, additional, Morel, Chantal F, additional, Morris, William R., additional, Moster, Mark L., additional, Mourani, John, additional, Muccioli, Cristina, additional, Mudumbai, Raghu C., additional, Murillo-Lopez, Fernando H., additional, Myint, Shoib, additional, Nagra, Parveen K, additional, Naoumi, A, additional, Nassif, John, additional, Nee, Michelle T., additional, Netto, Marcelo V., additional, Ng, John D., additional, Nguyen, Hau T., additional, Nguyen, Quan Dong, additional, O'Day, Denis M., additional, O'Day, A. Justin, additional, O'Halloran, Henry S., additional, O'Keefe, Michael, additional, Okamoto, Fumiki, additional, Olson, Richard J., additional, Orcutt, James C., additional, Dundar, Sema Oruc, additional, Osbourne, Aaron, additional, Palazzi, Maristela Amaral, additional, Palmer, Earl A., additional, Papadopoulos, Maria, additional, Parnell, Jeffrey R., additional, Parsa, Cameron F., additional, Patel, Sanjay V., additional, Patterson, Emily, additional, Pendergast, Scott D., additional, Perry, Henry D., additional, Peters, Keith Roberson, additional, Po, Stephanie M., additional, Pokroy, Russell, additional, Putterman, Allen Michael, additional, Queiro, Rubén, additional, Rafiei, Nastaran, additional, Rahmani, Bahram, additional, Rapuano, Christopher J, additional, Rasheed, Karim, additional, Rathinam, S.R., additional, Raymond, Lawrence A., additional, Read, Russell W., additional, Lafayette, August, additional, Recchia, Franco M., additional, Reidy, James J., additional, Reynolds, Adam C., additional, Rich, Larry F., additional, Ritch, Robert, additional, Robb, Richard M., additional, Robert, Pierre-Yves, additional, Robertson, Joseph E., additional, Roh, Shiyoung, additional, Romanet, Jean-Paul, additional, Rootman, Jack, additional, Roque, Barbara L., additional, Roque, Manolette R., additional, Rosenbaum, Arthur L., additional, Rosenbaum, James Todd, additional, Roy, F. Hampton, additional, Rundle, Paul A., additional, Sadun, Alfredo A., additional, Saffra, Norman A., additional, Salim, Sarwat, additional, Samples, John R., additional, Santiago, Alvina Pauline D, additional, Saperstein, David A., additional, Saunders, Richard A., additional, Savage, James A., additional, Scheufele, Tina A., additional, Schiedler, Vivian, additional, Schlesinger, Thomas K., additional, Schlossman, Abraham, additional, Schwartz, Lee K., additional, Scott, Ingrid U., additional, Scruggs, Jennifer, additional, Segal, Ernesto I., additional, Shalaby, Ismail A., additional, Sheikh, Aziz, additional, Sheppard, John D., additional, Sherman, Mark D., additional, Shields, Carol L., additional, Shields, Jerry A., additional, Singh, Amarpreet, additional, Singh, Christopher N., additional, Singman, Eric L., additional, Siracuse-Lee, Donna, additional, Smalley, Aaron D., additional, Smith, Patricia W., additional, Solomon, Anthony W., additional, Souhail, Hassane, additional, Spitzberg, Daniel H., additional, Spoor, Thomas C., additional, Stamper, Robert L., additional, Stark, Walter J., additional, Steele, Eric A., additional, Steinemann, Thomas L., additional, Stout, Ann U., additional, Stout, J. Timothy, additional, Stulting, R. Doyle, additional, Sugar, Alan, additional, Sugar, Joel, additional, Suh, Donny W., additional, Suhler, Eric B., additional, Sullivan, John H., additional, Sutphin, John Everett, additional, Swan, Kenneth C., additional, Tabbara, Khalid F., additional, Tamber, Mandeep S., additional, Tanna, Angelo P., additional, Tatlipinar, Sinan, additional, Tayani, Ramin, additional, Teichmann, Klaus D., additional, Terry, Mark A., additional, Tham, Clement Chee Yung, additional, Therzaz, A., additional, Thuret, Gilles, additional, Tinley, Christopher Graham, additional, Tongue, Andrea C., additional, Torres, Rodrigo J., additional, Tower, Robert N., additional, Traboulsi, Elias I, additional, Trikha, Rupan, additional, Tripathi, Brenda J., additional, Tripathi, Ramesh C., additional, Tugal-Tutkun, Ilknur, additional, Tung, Irene, additional, Evendingen, Judith A. M. Van, additional, Vaudaux, Jean D., additional, Wairagkar, Niteen S, additional, Walrath, Joseph D., additional, Walsh, Rory McConn, additional, Walton, David S., additional, Warwar, Ronald E., additional, Watson, Peter G., additional, Weiter, John J., additional, Weleber, Richard G., additional, Wertz, Fleming D., additional, Westra, Igor, additional, Wheeler, David T., additional, Wilkinson, Charles P., additional, Wilson, David J., additional, Wilson, M. Edward, additional, Wilson, Matthew W., additional, Wilson, Steven E, additional, Wobig, John L., additional, Wood, Terry D., additional, Wu, Lihteh, additional, Yalcinbayir, Ozgur, additional, Ying, Howard Shann-Cherng, additional, Youssef, Peter N., additional, and Zaidman, Gerald W., additional
- Published
- 2008
- Full Text
- View/download PDF
20. Laser and surgical treatment of glaucoma
- Author
-
Wilkins, Mark R, primary, Shah, Peter, additional, and Khaw, Peng T, additional
- Published
- 2007
- Full Text
- View/download PDF
21. Associations with Intraocular Pressure in a Large Cohort: Results from the UK Biobank
- Author
-
Chan, Michelle PY, Grossi, Carlota M, Khawaja, Anthony P, Yip, Jennifer LY, Khaw, Kay-Tee, Patel, Praveen J, Khaw, Peng T, Morgan, James E, Vernon, Stephen A, Foster, Paul J, and UK Biobank Eye and Vision Consortium
- Subjects
genetic structures - Abstract
PURPOSE: To describe the associations of physical and demographic factors with Goldmann-correlated intraocular pressure (IOPg) and corneal-compensated intraocular pressure (IOPcc) in a British cohort. DESIGN: Cross-sectional study within the UK Biobank, a large-scale multisite cohort study in the United Kingdom. PARTICIPANTS: We included 110 573 participants from the UK Biobank with intraocular pressure (IOP) measurements available. Their mean age was 57 years (range, 40-69 years); 54% were women, and 90% were white. METHODS: Participants had 1 IOP measurement made on each eye using the Ocular Response Analyzer noncontact tonometer. Linear regression models were used to assess the associations of IOP with physical and demographic factors. MAIN OUTCOME MEASURES: The IOPg and IOPcc. RESULTS: The mean IOPg was 15.72 mmHg (95% confidence interval [CI], 15.70-15.74 mmHg), and the mean IOPcc was 15.95 mmHg (15.92-15.97 mmHg). After adjusting for covariates, IOPg and IOPcc were both significantly associated with older age, male sex, higher systolic blood pressure (SBP), faster heart rate, greater myopia, self-reported glaucoma, and colder season (all P < 0.001). The strongest determinants of both IOPg and IOPcc were SBP (partial R(2): IOPg 2.30%, IOPcc 2.26%), followed by refractive error (IOPg 0.60%, IOPcc 1.04%). The following variables had different directions of association with IOPg and IOPcc: height (-0.77 mmHg/m IOPg; 1.03 mmHg/m IOPcc), smoking (0.19 mmHg IOPg, -0.35 mmHg IOPcc), self-reported diabetes (0.41 mmHg IOPg, -0.05 mmHg IOPcc), and black ethnicity (-0.80 mmHg IOPg, 0.77 mmHg IOPcc). This suggests that height, smoking, diabetes, and ethnicity are related to corneal biomechanical properties. The increase in both IOPg and IOPcc with age was greatest among those of mixed ethnicities, followed by blacks and whites. The same set of covariates explained 7.4% of the variability of IOPcc but only 5.3% of the variability of IOPg. CONCLUSIONS: This analysis of associations with IOP in a large cohort demonstrated that some variables clearly have different associations with IOPg and IOPcc, and that these 2 measurements may reflect different biological characteristics.
- Published
- 2016
22. Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: Two-Year Results from a Randomized, Multicenter Study.
- Author
-
Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, and Khaw PT
- Subjects
- Adult, Humans, Intraocular Pressure, Mitomycin, Prospective Studies, Middle Aged, Aged, Aged, 80 and over, Glaucoma surgery, Glaucoma, Open-Angle surgery, Glaucoma, Open-Angle drug therapy, Trabeculectomy methods
- Abstract
Purpose: To compare the effectiveness and safety of the MicroShunt (Santen Inc) versus trabeculectomy in patients with primary open-angle glaucoma (POAG)., Design: Prospective, randomized, multicenter trial conducted in the United States and Europe., Participants: Adult patients (aged 40-85 years) with mild to severe POAG inadequately controlled on maximum tolerated medical therapy and intraocular pressure (IOP) ≥ 15 mmHg and ≤ 40 mmHg., Methods: Patients were randomized 3:1 to stand-alone MicroShunt implantation (n = 395) or trabeculectomy (n = 132), both augmented with mitomycin C (MMC) 0.2 mg/ml for 2 minutes., Main Outcome Measures: The primary effectiveness end point was surgical success, defined as ≥ 20% reduction in mean diurnal IOP from baseline with no increase in glaucoma medications. Secondary end points included changes in mean IOP and medication use from baseline and the need for postoperative interventions., Results: At 2 years, the rate of surgical success was lower in the MicroShunt group than in the trabeculectomy group (50.6% vs. 64.4%, P = 0.005). Mean diurnal IOP was reduced from 21.1 ± 4.9 mmHg at baseline to 13.9 ± 3.9 mmHg at 24 months in the MicroShunt group and from 21.1 ± 5.0 mmHg at baseline to 10.7 ± 3.7 mmHg at 24 months in the trabeculectomy group (P < 0.001 compared with baseline in both groups). Mean medication use decreased from 3.1 to 0.9 in the MicroShunt group and from 2.9 to 0.4 in the trabeculectomy group (P < 0.001 compared with baseline in both groups). Adverse events at 2 years were generally similar in the 2 groups, except that hypotony was more common in eyes undergoing trabeculectomy (51.1% vs. 30.9%, P < 0.001). Repositioning or explantation of the implant occurred in 6.8% of MicroShunt patients. The majority of these patients had device removal at the time of subsequent glaucoma surgery. Vision-threatening complications were uncommon in both groups., Conclusion: At 2 years, both the MicroShunt and trabeculectomy provided significant reductions in IOP and medication use, with trabeculectomy continuing to have greater surgical success., Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article., (Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. Corneal Endothelial Cell Density Loss after Glaucoma Surgery Alone or in Combination with Cataract Surgery: A Systematic Review and Meta-analysis.
- Author
-
Fang CEH, Mathew RG, Khaw PT, and Henein C
- Subjects
- Corneal Endothelial Cell Loss diagnosis, Corneal Endothelial Cell Loss etiology, Endothelial Cells, Humans, Cataract complications, Glaucoma surgery, Glaucoma Drainage Implants adverse effects, Glaucoma, Open-Angle complications, Glaucoma, Open-Angle surgery
- Abstract
Topic: Corneal endothelial cell density (ECD) loss after glaucoma surgery with or without cataract surgery., Clinical Relevance: Corneal ECD loss may occur as the result of intraoperative surgical trauma in glaucoma surgery or postoperatively with chronic endothelial cell trauma or irritation., Methods: Glaucoma filtration surgery or microinvasive glaucoma surgery (MIGS) in participants with ocular hypertension, primary and secondary open-angle glaucoma, normal-tension glaucoma, and angle-closure glaucoma were included. Electronic databases searched in December 2021 included MEDLINE, Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, the International Prospective Register of Systematic Reviews, Food and Drug Administration (FDA) Premarket Approval, and FDA 510(k)., Results: A total of 39 studies were included in quantitative synthesis. Twelve months after suprachoroidal MIGS, mean ECD loss was 282 cells/mm
2 (95% confidence interval [CI], 220-345; P < 0.00001; chi-square = 0.06; I2 = 0%; 2 studies; very low certainty). Mean ECD loss after Schlemm's canal implantable devices was 338 cells/mm2 (95% CI, 185-491; P < 0.0001; chi-square = 0.08; I2 = 0%; 2 studies; low certainty) at 12 months. Mean ECD loss was 64 cells/mm2 (95% CI, 21-107; P = 0.004; chi-square = 4.55; I2 = 0%; 6 studies; low certainty) after Schlemm's canal procedures (without implantable devices) at 12 months. At 12 months, the mean ECD loss after trabeculectomy was 33 cells/mm2 (95% CI, -38 to 105, P = 0.36, chi-square = 1.17; I2 = 0%; moderate certainty). At 12 months, mean ECD loss was 121 cells/mm2 (95% CI, 53-189; P = 0.0005; chi-square = 3.00; I2 = 0%; 5 studies; low certainty) after Express (Alcon) implantation. When compared with the control fellow eye, aqueous shunt surgery reduced ECD by 5.75% (95% CI, -0.93 to 12.43; P = 0.09, chi-square = 1.32; I2 = 0%; low certainty) and 8.11% ECD loss (95% CI, 0.06-16.16 P = 0.05; chi-square = 1.93; I2 = 48%) at 12 and 24 months, respectively., Conclusions: Overall, there is low certainty evidence to suggest that glaucoma surgery involving long-term implants has a greater extent of ECD loss than glaucoma filtration surgeries without the use of implants. The results of this review support follow-up beyond 36 months to assess ECD loss and corneal decompensation after implantation of glaucoma drainage implants., (Copyright © 2022. Published by Elsevier Inc.)- Published
- 2022
- Full Text
- View/download PDF
24. Alcohol Consumption and Incident Cataract Surgery in Two Large UK Cohorts.
- Author
-
Chua SYL, Luben RN, Hayat S, Broadway DC, Khaw KT, Warwick A, Britten A, Day AC, Strouthidis N, Patel PJ, Khaw PT, Foster PJ, and Khawaja AP
- Subjects
- Alcohol Drinking epidemiology, Cataract epidemiology, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Postoperative Complications etiology, Prospective Studies, Risk Factors, United Kingdom epidemiology, Alcohol Drinking adverse effects, Cataract complications, Postoperative Complications epidemiology, Self Report
- Abstract
Purpose: To examine the association of alcohol consumption and type of alcoholic beverage with incident cataract surgery in 2 large cohorts., Design: Longitudinal, observational study., Participants: We included 469 387 participants of UK Biobank with a mean age of 56 years and 23 162 participants of European Prospective Investigation of Cancer (EPIC)-Norfolk with a mean age of 59 years., Methods: Self-reported alcohol consumption at baseline was ascertained by a touchscreen questionnaire in UK Biobank and a food-frequency questionnaire in EPIC-Norfolk. Cases were defined as participants undergoing cataract surgery in either eye as ascertained via data linkage to National Health Service procedure statistics. We excluded participants with cataract surgery up to 1 year after the baseline assessment visit or those with self-reported cataract at baseline. Cox proportional hazards models were used to examine the associations of alcohol consumption with incident cataract surgery, adjusted for age, sex, ethnicity, Townsend deprivation index, body mass index (BMI), smoking, and diabetes status., Main Outcome Measures: Incident cataract surgery., Results: There were 19 011 (mean cohort follow-up of 95 months) and 4573 (mean cohort follow-up of 193 months) incident cases of cataract surgery in UK Biobank and EPIC-Norfolk, respectively. Compared with nondrinkers, drinkers were less likely to undergo cataract surgery in UK Biobank (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.85-0.93) and EPIC-Norfolk (HR, 0.90; 95% CI, 0.84-0.97) after adjusting for covariables. Among alcohol consumers, greater alcohol consumption was associated with a reduced risk of undergoing cataract surgery in EPIC-Norfolk (P < 0.001), whereas a U-shaped association was observed in the UK Biobank. Compared with nondrinkers, subgroup analysis by type of alcohol beverage showed the strongest protective association with wine consumption; the risk of incident cataract surgery was 23% and 14% lower among those in the highest category of wine consumption in EPIC-Norfolk and UK Biobank, respectively., Conclusions: Our findings suggest a lower risk of undergoing cataract surgery with low to moderate alcohol consumption. The association was particularly apparent with wine consumption. We cannot exclude the possibility of residual confounding, and further studies are required to determine whether this association is causal in nature., (Copyright © 2021 American Academy of Ophthalmology. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
25. Comparison of Associations with Different Macular Inner Retinal Thickness Parameters in a Large Cohort: The UK Biobank.
- Author
-
Khawaja AP, Chua S, Hysi PG, Georgoulas S, Currant H, Fitzgerald TW, Birney E, Ko F, Yang Q, Reisman C, Garway-Heath DF, Hammond CJ, Khaw PT, Foster PJ, Patel PJ, and Strouthidis N
- Subjects
- Adult, Age Factors, Aged, Area Under Curve, Biological Specimen Banks, Body Constitution, Body Mass Index, Cohort Studies, Cross-Sectional Studies, Ethnicity, Female, Humans, Intraocular Pressure physiology, Male, Middle Aged, ROC Curve, Sex Factors, Tomography, Optical Coherence, United Kingdom, Nerve Fibers physiology, Retinal Ganglion Cells physiology
- Abstract
Purpose: To describe and compare associations with macular retinal nerve fiber layer (mRNFL), ganglion cell complex (GCC), and ganglion cell-inner plexiform layer (GCIPL) thicknesses in a large cohort., Design: Cross-sectional study., Participants: We included 42 044 participants in the UK Biobank. The mean age was 56 years., Methods: Spectral-domain OCT macular images were segmented and analyzed. Corneal-compensated intraocular pressure (IOPcc) was measured with the Ocular Response Analyzer (Reichert, Corp., Buffalo, NY). Multivariable linear regression was used to examine associations with mean mRNFL, GCC, and GCIPL thicknesses. Factors examined were age, sex, ethnicity, height, body mass index (BMI), smoking status, alcohol intake, Townsend deprivation index, education level, diabetes status, spherical equivalent, and IOPcc., Main Outcome Measures: Thicknesses of mRNFL, GCC, and GCIPL., Results: We identified several novel independent associations with thinner inner retinal thickness. Thinner inner retina was associated with alcohol intake (most significant for GCIPL: -0.46 μm for daily or almost daily intake compared with special occasion only or never [95% confidence interval (CI), 0.61-0.30]; P = 1.1×10
-8 ), greater social deprivation (most significant for GCIPL: -0.28 μm for most deprived quartile compared with least deprived quartile [95% CI, -0.42 to -0.14]; P = 6.6×10-5 ), lower educational attainment (most significant for mRNFL: -0.36 μm for less than O level compared with degree level [95% CI, -0.45 to 0.26]; P = 2.3×10-14 ), and nonwhite ethnicity (most significant for mRNFL comparing blacks with whites: -1.65 μm [95% CI, -1.86 to -1.43]; P = 2.4×10-50 ). Corneal-compensated intraocular pressure was associated most significantly with GCIPL (-0.04 μm/mmHg [95% CI, -0.05 to -0.03]; P = 4.0×10-10 ) and was not associated significantly with mRNFL (0.00 μm/mmHg [95% CI, -0.01 to 0.01]; P = 0.77). The variables examined explained a greater proportion of the variance of GCIPL (11%) than GCC (6%) or mRNFL (7%)., Conclusions: The novel associations we identified may be important to consider when using inner retinal parameters as a diagnostic tool. Associations generally were strongest with GCIPL, particularly for IOP. This suggests that GCIPL may be the superior inner retinal biomarker for macular pathophysiologic processes and especially for glaucoma., (Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
26. The Oculome Panel Test: Next-Generation Sequencing to Diagnose a Diverse Range of Genetic Developmental Eye Disorders.
- Author
-
Patel A, Hayward JD, Tailor V, Nyanhete R, Ahlfors H, Gabriel C, Jannini TB, Abbou-Rayyah Y, Henderson R, Nischal KK, Islam L, Bitner-Glindzicz M, Hurst J, Valdivia LE, Zanolli M, Moosajee M, Brookes J, Papadopoulos M, Khaw PT, Cullup T, Jenkins L, Dahlmann-Noor A, and Sowden JC
- Subjects
- Adolescent, Child, Child, Preschool, Female, Genome, Human, Humans, Infant, Infant, Newborn, Male, Pedigree, DNA Copy Number Variations genetics, Eye Abnormalities diagnosis, Eye Abnormalities genetics, High-Throughput Nucleotide Sequencing methods, Molecular Diagnostic Techniques, Mutation genetics, Proteome genetics
- Abstract
Purpose: To develop a comprehensive next-generation sequencing panel assay that screens genes known to cause developmental eye disorders and inherited eye disease and to evaluate its diagnostic yield in a pediatric cohort with malformations of the globe, anterior segment anomalies, childhood glaucoma, or a combination thereof., Design: Evaluation of diagnostic test., Participants: Two hundred seventy-seven children, 0 to 16 years of age, diagnosed with nonsyndromic or syndromic developmental eye defects without a genetic diagnosis., Methods: We developed a new oculome panel using a custom-designed Agilent SureSelect QXT target capture method (Agilent Technologies, Santa Clara, CA) to capture and perform parallel high-throughput sequencing analysis of 429 genes associated with eye disorders. Bidirectional Sanger sequencing confirmed suspected pathogenic variants., Main Outcome Measures: Collated clinical details and oculome molecular genetic results., Results: The oculome design covers 429 known eye disease genes; these are subdivided into 5 overlapping virtual subpanels for anterior segment developmental anomalies including glaucoma (ASDA; 59 genes), microphthalmia-anophthalmia-coloboma (MAC; 86 genes), congenital cataracts and lens-associated conditions (70 genes), retinal dystrophies (RET; 235 genes), and albinism (15 genes), as well as additional genes implicated in optic atrophy and complex strabismus (10 genes). Panel development and testing included analyzing 277 clinical samples and 3 positive control samples using Illumina sequencing platforms; more than 30× read depth was achieved for 99.5% of the targeted 1.77-Mb region. Bioinformatics analysis performed using a pipeline based on Freebayes and ExomeDepth to identify coding sequence and copy number variants, respectively, resulted in a definitive diagnosis in 68 of 277 samples, with variability in diagnostic yield between phenotypic subgroups: MAC, 8.2% (8 of 98 cases solved); ASDA, 24.8% (28 of 113 cases solved); other or syndromic, 37.5% (3 of 8 cases solved); RET, 42.8% (21 of 49 cases solved); and congenital cataracts and lens-associated conditions, 88.9% (8 of 9 cases solved)., Conclusions: The oculome test diagnoses a comprehensive range of genetic conditions affecting the development of the eye, potentially replacing protracted and costly multidisciplinary assessments and allowing for faster targeted management. The oculome enabled molecular diagnosis of a significant number of cases in our sample cohort of varied ocular birth defects., (Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
27. Childhood Lensectomy Is Associated with Static and Dynamic Reduction in Schlemm Canal Size: A Biomechanical Hypothesis of Glaucoma after Lensectomy.
- Author
-
Daniel MC, Dubis AM, Theodorou M, Quartilho A, Adams G, Brookes J, Papadopoulos M, Khaw PT, and Dahlmann-Noor AH
- Subjects
- Accommodation, Ocular physiology, Adolescent, Anterior Eye Segment diagnostic imaging, Biomechanical Phenomena, Child, Child, Preschool, Cross-Sectional Studies, Female, Glaucoma physiopathology, Humans, Lens Implantation, Intraocular, Male, Pseudophakia physiopathology, Tomography, Optical Coherence methods, Cataract Extraction adverse effects, Glaucoma etiology, Limbus Corneae physiopathology, Trabecular Meshwork physiopathology
- Abstract
Purpose: To compare Schlemm canal (SC) and trabecular meshwork (TM) in children with healthy eyes and those with and without glaucoma after lensectomy., Design: Cross-sectional observational study., Participants: Fifty children 4 to 16 years of age with healthy eyes and 48 children who underwent lensectomy (124 healthy and 72 postlensectomy eyes)., Methods: Anterior segment (AS) OCT (Tomey SS-1000 CASIA; Tomey, Nagoya, Japan) of the nasal iridocorneal angle at 2 levels of accommodative effort (2.5 diopters [D] and 15 D). For each parameter and state of accommodation, a random effects model was fitted to estimate differences between healthy eyes and eyes with history of lensectomy., Main Outcome Measures: Dimensions of SC and TM and conventional AS OCT iridocorneal angle measurements., Results: The horizontal diameter of SC and its cross-sectional area (CSA) are significantly smaller in eyes that have undergone lensectomy versus healthy eyes. Accommodative effort increases SC size in healthy eyes, but not in eyes that have undergone lensectomy., Conclusions: Lensectomy is associated with a reduction in SC size and a loss of physiologic SC dilatation during accommodative effort, which may reflect a reduction in outflow facility and may contribute to the development of glaucoma after lensectomy., (Copyright © 2018 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
28. Electrospun formulations of bevacizumab for sustained release in the eye.
- Author
-
Angkawinitwong U, Awwad S, Khaw PT, Brocchini S, and Williams GR
- Subjects
- Corneal Injuries metabolism, Delayed-Action Preparations chemical synthesis, Delayed-Action Preparations chemistry, Delayed-Action Preparations pharmacokinetics, Delayed-Action Preparations pharmacology, Humans, Hydrogen-Ion Concentration, Macular Degeneration metabolism, Bevacizumab chemistry, Bevacizumab pharmacokinetics, Bevacizumab pharmacology, Corneal Injuries drug therapy, Eye metabolism, Macular Degeneration drug therapy, Polyesters chemistry, Polyesters pharmacokinetics, Polyesters pharmacology
- Abstract
Medicines based on vascular endothelial growth factor (VEGF) neutralising antibodies such as bevacizumab have revolutionized the treatment of age related macular degeneration (AMD), a common blinding disease, and have great potential in preventing scarring after surgery or accelerating the healing of corneal injuries. However, at present frequent invasive injections are required to deliver these antibodies. Such administration is uncomfortable for patients and expensive for health service providers. Much effort is thus focused on developing dosage forms that can be administered less frequently. Here we use electrospinning to prepare a solid form of bevacizumab designed for prolonged release while maintaining antibody stability. Electrospun fibers were prepared with bevacizumab encapsulated in the core, surrounded by a poly-ε-caprolactone sheath. The fibers were generated using aqueous bevacizumab solutions buffered at two different pH values: 6.2 (the pH of the commercial product; F
beva ) and 8.3 (the isoelectric point of bevacizumab; FbevaP ). The fibers had smooth and cylindrical morphologies, with diameters of ca. 500nm. Both sets of bevacizumab loaded fibers gave sustained release profiles in an in vitro model of the subconjunctival space of the eye. Fbeva displayed first order kinetics with t1/2 of 11.4±4.4 days, while FbevaP comprises a zero-order reservoir type release system with t1/2 of 52.9±14.8 days. Both SDS-PAGE and surface plasmon resonance demonstrate that the bevacizumab in FbevaP did not undergo degradation during fiber fabrication or release. In contrast, the antibody released from Fbeva had degraded, and failed to bind to VEGF. Our results demonstrate that pH control is crucial to maintain antibody stability during the fabrication of core/shell fibers and ensure release of functional protein., Statement of Significance: Bevacizumab is a potent protein drug which is highly effective in the treatment of degenerative conditions in the eye. To be effective, frequent injections into the eye are required, which is deeply unpleasant for patients and expensive for healthcare providers. Alternative methods of administration are thus highly sought after. In our work, we use the electrospinning technique to prepare fiber-based formulations loaded with bevacizumab. By careful control of the experimental parameters we are able to stabilize the protein during processing and ensure a constant rate of release over more than two months in vitro. These fibers could thus be used to reduce the frequency of dosing required, reducing cost and improving patient outcomes., (Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
29. Quality of Life and Functional Vision in Children with Glaucoma.
- Author
-
Dahlmann-Noor A, Tailor V, Bunce C, Abou-Rayyah Y, Adams G, Brookes J, Khaw PT, and Papadopoulos M
- Subjects
- Adolescent, Child, Child, Preschool, Cross-Sectional Studies, Female, Glaucoma physiopathology, Humans, Intraocular Pressure physiology, Male, Activities of Daily Living, Glaucoma psychology, Quality of Life, Self Report, Surveys and Questionnaires, Visual Acuity physiology
- Abstract
Purpose: To evaluate the effect of glaucoma on functional vision and on vision-related (VR) and health-related (HR) quality of life (QoL) in children up to 16 years of age., Design: Cross-sectional observational study., Participants: One hundred nineteen children 2 to 16 years of age (mean age, 9.4 years; standard deviation [SD], 4.56 years) with glaucoma and their parents., Methods: Completion of 3 validated instruments for children to assess (1) functional visual ability (FVA) with the Cardiff Visual Ability Questionnaire for Children (CVAQC), (2) VR QoL with the Impact of Vision Impairment for Children (IVI-C), and (3) HR QoL with the Pediatric Quality of Life Inventory (PedsQL) version 4.0., Main Outcome Measures: Cardiff Visual Ability Questionnaire for Children, IVI-C, and PedsQL scores., Results: Scores for FVA, VR QoL, and HR QoL were reduced in children with glaucoma: median CVAQC score, -1.24 (interquartile range [IQR], -2.2 to -0.11; range, -3.00 higher visual ability to +2.80 lower visual ability); mean IVI-C score, 67.3 (SD, 14.4; normal VR QoL, 96); median PedsQL self-report, 78.8 (IQR, 67.4-90.2); parent report, 71.2 (IQR, 55.7-85.8); and family impact score, 74.3 (IQR, 56.9-88.5; normal HR QoL, 100). Psychosocial subscores were lower than physical subscores on the PedsQL. Older children reported less impairment on CVAQC, IVI-C, and PedsQL than younger children. Parents reported greater impact on their child's HR QoL than children reported themselves., Conclusions: Glaucoma and its management have a marked impact on a child's FVA and QoL. Children with glaucoma report HR QoL scores similar to those described by children with severe congenital cardiac defects, who have undergone liver transplants, or who have acute lymphoblastic leukemia., (Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
30. Associations with Intraocular Pressure in a Large Cohort: Results from the UK Biobank.
- Author
-
Chan MP, Grossi CM, Khawaja AP, Yip JL, Khaw KT, Patel PJ, Khaw PT, Morgan JE, Vernon SA, and Foster PJ
- Subjects
- Adult, Aged, Aging physiology, Blood Pressure physiology, Body Mass Index, Cohort Studies, Cross-Sectional Studies, Databases, Factual, Female, Heart Rate physiology, Humans, Male, Middle Aged, National Health Programs, Prospective Studies, Refraction, Ocular physiology, Surveys and Questionnaires, United Kingdom, Cornea physiology, Intraocular Pressure physiology, Tonometry, Ocular
- Abstract
Purpose: To describe the associations of physical and demographic factors with Goldmann-correlated intraocular pressure (IOPg) and corneal-compensated intraocular pressure (IOPcc) in a British cohort., Design: Cross-sectional study within the UK Biobank, a large-scale multisite cohort study in the United Kingdom., Participants: We included 110 573 participants from the UK Biobank with intraocular pressure (IOP) measurements available. Their mean age was 57 years (range, 40-69 years); 54% were women, and 90% were white., Methods: Participants had 1 IOP measurement made on each eye using the Ocular Response Analyzer noncontact tonometer. Linear regression models were used to assess the associations of IOP with physical and demographic factors., Main Outcome Measures: The IOPg and IOPcc., Results: The mean IOPg was 15.72 mmHg (95% confidence interval [CI], 15.70-15.74 mmHg), and the mean IOPcc was 15.95 mmHg (15.92-15.97 mmHg). After adjusting for covariates, IOPg and IOPcc were both significantly associated with older age, male sex, higher systolic blood pressure (SBP), faster heart rate, greater myopia, self-reported glaucoma, and colder season (all P < 0.001). The strongest determinants of both IOPg and IOPcc were SBP (partial R(2): IOPg 2.30%, IOPcc 2.26%), followed by refractive error (IOPg 0.60%, IOPcc 1.04%). The following variables had different directions of association with IOPg and IOPcc: height (-0.77 mmHg/m IOPg; 1.03 mmHg/m IOPcc), smoking (0.19 mmHg IOPg, -0.35 mmHg IOPcc), self-reported diabetes (0.41 mmHg IOPg, -0.05 mmHg IOPcc), and black ethnicity (-0.80 mmHg IOPg, 0.77 mmHg IOPcc). This suggests that height, smoking, diabetes, and ethnicity are related to corneal biomechanical properties. The increase in both IOPg and IOPcc with age was greatest among those of mixed ethnicities, followed by blacks and whites. The same set of covariates explained 7.4% of the variability of IOPcc but only 5.3% of the variability of IOPg., Conclusions: This analysis of associations with IOP in a large cohort demonstrated that some variables clearly have different associations with IOPg and IOPcc, and that these 2 measurements may reflect different biological characteristics., (Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
31. Long-Term Outcomes of Trabeculectomy Augmented with Mitomycin C Undertaken within the First 2 Years of Life.
- Author
-
Jayaram H, Scawn R, Pooley F, Chiang M, Bunce C, Strouthidis NG, Khaw PT, and Papadopoulos M
- Subjects
- Antihypertensive Agents administration & dosage, Combined Modality Therapy, Conjunctiva drug effects, Female, Follow-Up Studies, Glaucoma congenital, Glaucoma physiopathology, Humans, Infant, Intraocular Pressure physiology, Male, Postoperative Complications, Retrospective Studies, Trabecular Meshwork physiopathology, Treatment Outcome, Visual Acuity physiology, Alkylating Agents administration & dosage, Glaucoma surgery, Mitomycin administration & dosage, Trabecular Meshwork surgery, Trabeculectomy methods
- Abstract
Purpose: To evaluate the long-term effectiveness and safety of mitomycin C (MMC)-augmented trabeculectomy undertaken within the first 2 years of life for the surgical management of glaucoma., Design: Retrospective, consecutive, noncomparative case series., Participants: All children who underwent MMC-augmented trabeculectomy within 2 years of birth between May 2002 and November 2012., Methods: The medical records of 40 consecutive eyes of 26 children who underwent surgery by a single surgeon were reviewed. Data collected during routine clinical care were analyzed., Main Outcome Measures: Assessment of clinical outcomes included intraocular pressure (IOP), final visual acuity, bleb morphology, surgical complications (early and late), postoperative interventions, and further glaucoma surgery performed. Surgical success was defined as final IOP of 5 mmHg or more and of 21 mmHg or less, with anti-glaucoma medications (qualified success) and without (complete success), stable ocular dimensions and optic disc cupping, and no further glaucoma surgery (including needling) or loss of light perception. Surgical outcomes were evaluated using Kaplan-Meier life table analysis., Results: Forty eyes of 26 children were studied over a mean follow-up period of 62.8 months. Most cases (80%) were of primary congenital glaucoma after failed goniotomy surgery. Cumulative probabilities of survival at 1, 5, and 7 years were 78%, 67%, and 60%, respectively. Of eyes regarded as successful, 96% (25/26 eyes) had controlled IOP without topical medication and 44% achieved visual acuity of 20/40 or better. In only 1 of the 40 eyes did a cystic avascular bleb develop, with all the other eyes being non-cystic in nature (diffuse and elevated or flat) at final follow-up. Sixty-four percent (9/14 eyes) of cases regarded as failures ultimately underwent glaucoma drainage device implantation., Conclusions: A contemporary pediatric trabeculectomy technique augmented with MMC is an effective procedure in the management of glaucoma within the first 2 years of life, as shown by the successful long-term outcomes and low incidence of sight-threatening complications. Trabeculectomy after failed goniotomy surgery or as a primary surgical intervention may offer a phakic infant with glaucoma an excellent opportunity to achieve long-term control of IOP without medications and may be associated with optimal visual outcomes., (Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
32. The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development.
- Author
-
Awwad S, Lockwood A, Brocchini S, and Khaw PT
- Subjects
- Albumins metabolism, Bevacizumab pharmacokinetics, Drug Delivery Systems, Eye Diseases drug therapy, Humans, Intravitreal Injections, Models, Biological, Ophthalmic Solutions, Reproducibility of Results, Triamcinolone Acetonide pharmacokinetics, Viscosity, Vitreous Body metabolism, Aqueous Humor metabolism, Drug Evaluation, Preclinical methods, Pharmacokinetics
- Abstract
A 2-compartment in vitro eye flow model has been developed to estimate ocular drug clearance by the anterior aqueous outflow pathway. The model is designed to accelerate the development of longer-acting ophthalmic therapeutics. Dye studies show aqueous flow is necessary for a molecule injected into the vitreous cavity to clear from the model. The clearance times of proteins can be estimated by collecting the aqueous outflow, which was first conducted with bevacizumab using phosphate-buffered saline in the vitreous cavity. A simulated vitreous solution was then used and ranibizumab (0.5 mg) displayed a clearance time of 8.1 ± 3.1 days, which is comparable to that observed in humans. The model can estimate drug release from implants or the dissolution of suspensions as a first step in their clearance mechanism, which will be the rate-limiting step for the overall resident time of a candidate dosage form in the vitreous. A suspension of triamcinolone acetonide (Kenalog®) (4.0 mg) displayed clearance times spanning 26-28 days. These results indicate that the model can be used to determine in vitro-in vivo correlations in preclinical studies to develop long-lasting therapeutics to treat blinding diseases at the back of the eye., (© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.)
- Published
- 2015
- Full Text
- View/download PDF
33. Primary congenital glaucoma.
- Author
-
Ko F, Papadopoulos M, and Khaw PT
- Subjects
- Humans, Glaucoma congenital
- Abstract
Primary congenital glaucoma (PCG) is the most common nonsyndromic glaucoma in infancy, which can lead to blindness, or a lifetime of vision when diagnosed and treated properly. PCG is more common in populations with a higher prevalence of consanguinity and is associated with CYP1B1 gene mutations which show variable expressivity and phenotypes. The immature angle appearance of PCG likely results from arrested development of tissues of neural crest origin in the third trimester, with the severity of abnormality varying according to the stage at which arrested development occurred. Classic symptoms at presentation include tearing, photophobia, blepharospasm, eye rubbing, and irritability. Examination may reveal elevated intraocular pressure, corneal edema, increased corneal diameter, Haab striae, or enlarged axial length. Angle surgery remains the first line treatment for PCG with a recent advance being circumferential trabeculotomy with the potential to incise the whole angle during one operation as oppose to an incremental approach and the associated multiple anesthetics. Once angle surgery fails, either trabeculectomy or glaucoma drainage device surgery may be appropriate., (© 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
34. Channelrhodopsins: visual regeneration and neural activation by a light switch.
- Author
-
G N, Tan A, Farhatnia Y, Rajadas J, Hamblin MR, Khaw PT, and Seifalian AM
- Subjects
- Animals, Channelrhodopsins, Humans, Light, Mice, Mice, Transgenic, Myocardial Contraction genetics, Myocardium metabolism, Retinal Degeneration genetics, Retinal Degeneration metabolism, Retinal Degeneration pathology, Retinal Ganglion Cells pathology, Spinal Cord Injuries genetics, Spinal Cord Injuries metabolism, Spinal Cord Injuries pathology, Membrane Potentials, Regeneration, Retinal Degeneration therapy, Retinal Ganglion Cells metabolism, Synaptic Transmission, Vision, Ocular
- Abstract
The advent of optogenetics provides a new direction for the field of neuroscience and biotechnology, serving both as a refined investigative tool and as potential cure for many medical conditions via genetic manipulation. Although still in its infancy, recent advances in optogenetics has made it possible to remotely manipulate in vivo cellular functions using light. Coined Nature Methods' 'Method of the Year' in 2010, the optogenetic toolbox has the potential to control cell, tissue and even animal behaviour. This optogenetic toolbox consists of light-sensitive proteins that are able to modulate membrane potential in response to light. Channelrhodopsins (ChR) are light-gated microbial ion channels, which were first described in green algae. ChR2 (a subset of ChR) is a seven transmembrane α helix protein, which evokes membrane depolarization and mediates an action potential upon photostimulation with blue (470 nm) light. By contrast to other seven-transmembrane proteins that require second messengers to open ion channels, ChR2 form ion channels themselves, allowing ultrafast depolarization (within 50 milliseconds of illumination). It has been shown that integration of ChR2 into various tissues of mice can activate neural circuits, control heart muscle contractions, and even restore breathing after spinal cord injury. More compellingly, a plethora of evidence has indicated that artificial expression of ChR2 in retinal ganglion cells can reinstate visual perception in mice with retinal degeneration., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
35. The Singapore 5-fluorouracil trial: intraocular pressure outcomes at 8 years.
- Author
-
Wong MH, Husain R, Ang BC, Gazzard G, Foster PJ, Htoon HM, Wong TT, Oen FT, Khaw PT, Seah SK, and Aung T
- Subjects
- Antihypertensive Agents therapeutic use, Combined Modality Therapy, Double-Blind Method, Follow-Up Studies, Glaucoma, Angle-Closure drug therapy, Glaucoma, Angle-Closure physiopathology, Glaucoma, Angle-Closure surgery, Glaucoma, Open-Angle drug therapy, Glaucoma, Open-Angle physiopathology, Glaucoma, Open-Angle surgery, Humans, Middle Aged, Proportional Hazards Models, Prospective Studies, Retrospective Studies, Risk Factors, Singapore, Tonometry, Ocular, Treatment Failure, Treatment Outcome, Visual Fields, Antimetabolites therapeutic use, Fluorouracil therapeutic use, Glaucoma, Angle-Closure therapy, Glaucoma, Open-Angle therapy, Intraocular Pressure drug effects, Trabeculectomy
- Abstract
Objective: To report the 8-year outcomes of Asian subjects who underwent trabeculectomy augmented by intraoperative 5-fluorouracil (5-FU) or placebo., Design: Retrospective review of a randomized controlled trial., Participants: Subjects with primary open-angle or angle-closure glaucoma., Methods: Study subjects were prospectively followed up for 3 years. After the last subject recruited had completed 8 years of follow-up, the charts of all subjects were reviewed to capture data from the year 3 visit onward. Kaplan-Meier survival function with Cox regression was performed to identify risk factors associated with trabeculectomy failure at 8 years., Main Outcome Measures: The primary outcome was trabeculectomy failure defined as intraocular pressure (IOP) >21 or <6 mmHg on 2 consecutive occasions after the first 6 weeks after surgery, repeat glaucoma surgery, or loss of light perception. Further end points were defined at IOP levels >17 and >14 mmHg. Secondary outcomes included IOP at 8 years and number of glaucoma medications. Complete success was defined using IOP end points ≤ 21, ≤ 17, or ≤ 14 mmHg at 8 years without medications., Results: Of the 243 enrolled subjects, 170 (70.0%) completed 8 years follow-up, 86 in the 5-FU and 84 in the placebo group. There was no significant difference in failure rates at 8 years for the failure definitions of IOP >21 mmHg (11.6% of the 5-FU group vs. 16.7% of the placebo group; P = 1.00), IOP >17 mmHg (23.3% of the 5-FU group vs. 31% of the placebo group; P = 0.78), and IOP >14 mmHg (46.5% of the 5-FU group vs. 58.3% of the placebo group; P = 0.37). Mean IOP at 8 years was 13.7 mmHg in the 5-FU versus 14.4 mmHg in the placebo group (P = 0.24). Mean number of medications was 0.65 drops in the 5-FU versus 0.93 drops in the placebo group (P = 0.06). Complete success with IOP ≤ 21 mmHg at 8 years was achieved in 48 subjects (55.8%) in the 5-FU and 33 subjects (39.3%) in the placebo group (P = 0.09). Absence of bleb microcysts at 1 year, preoperative IOP, and number of bleb needlings performed within the first year were significantly associated with failure., Conclusions: There was no significant difference in IOP between the 5-FU and the placebo group at 8 years., Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article., (Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
36. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.
- Author
-
Foxton RH, Finkelstein A, Vijay S, Dahlmann-Noor A, Khaw PT, Morgan JE, Shima DT, and Ng YS
- Subjects
- Animals, Apoptosis drug effects, Caspases metabolism, Cell Death drug effects, Cells, Cultured, Cytoprotection drug effects, Disease Models, Animal, Glaucoma enzymology, Neuropilins metabolism, Neuroprotective Agents pharmacology, Neutralization Tests, Ocular Hypertension drug therapy, Ocular Hypertension enzymology, Ocular Hypertension pathology, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism, Rats, Rats, Sprague-Dawley, Retina drug effects, Retina enzymology, Retinal Ganglion Cells drug effects, Retinal Ganglion Cells enzymology, Retinal Ganglion Cells metabolism, Retinal Ganglion Cells pathology, Signal Transduction drug effects, Toxicity Tests, Acute, Vascular Endothelial Growth Factor Receptor-2 metabolism, Glaucoma drug therapy, Glaucoma pathology, Neuroprotective Agents therapeutic use, Retina pathology, Vascular Endothelial Growth Factor A metabolism
- Abstract
Vascular endothelial growth factor A (VEGF-A) is a validated therapeutic target in several angiogenic- and vascular permeability-related pathological conditions, including certain cancers and potentially blinding diseases, such as age-related macular degeneration and diabetic retinopathy. We and others have shown that VEGF-A also plays an important role in neuronal development and neuroprotection, including in the neural retina. Antagonism of VEGF-A function might therefore present a risk to neuronal survival as a significant adverse effect. Herein, we demonstrate that VEGF-A acts directly on retinal ganglion cells (RGCs) to promote survival. VEGF receptor-2 signaling via the phosphoinositide-3-kinase/Akt pathway was required for the survival response in isolated RGCs. These results were confirmed in animal models of staurosporine-induced RGC death and experimental hypertensive glaucoma. Importantly, we observed that VEGF-A blockade significantly exacerbated neuronal cell death in the hypertensive glaucoma model. Our findings highlight the need to better define the risks associated with use of VEGF-A antagonists in the ocular setting., (Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
37. Epilation for trachomatous trichiasis and the risk of corneal opacification.
- Author
-
Rajak SN, Habtamu E, Weiss HA, Bedri A, Gebre T, Genet A, Khaw PT, Bailey RL, Mabey DC, Gilbert CE, Emerson PM, and Burton MJ
- Subjects
- Adolescent, Adult, Aged, Body Mass Index, Cross-Sectional Studies, Eyelashes pathology, Female, Humans, Male, Middle Aged, Odds Ratio, Risk Assessment, Surveys and Questionnaires, Trachoma diagnosis, Trachoma ethnology, Treatment Outcome, Trichiasis diagnosis, Trichiasis ethnology, Corneal Opacity prevention & control, Hair Removal, Trachoma therapy, Trichiasis therapy
- Abstract
Purpose: Eight million people have trachomatous trichiasis (TT). The World Health Organization (WHO) recommends entropion surgery for TT regardless of severity. However, epilation is widely practiced for treating minor TT (1-5 lashes touching the globe). We report the frequency and effectiveness of patient-initiated epilation and its relationship to corneal opacity., Design: Cross-sectional baseline data of individuals recruited to 2 randomized, clinical trials., Participants: We included 2556 individuals (4310 eyes) with previously unoperated TT in ≥ 1 eye., Methods: A single ophthalmologist examined all participants for signs of trachoma using WHO grading systems with additional assessment of entropion grading, location and number of trichiatic lashes, and evidence of epilation. A questionnaire enquired about epilation practices., Main Outcome Measures: The association between epilation and degree of corneal opacity. Epilation practices of TT patients., Results: Central corneal scarring was present in 1436 (33%) eyes. Entropion was absent/mild in 2328 (54%) eyes, moderate in 1259 (29.2%), and severe in 723 (16.8%). The median number of lashes touching the eye was 2 (interquartile range, 1-5; range, 0-133). There was clinical evidence of epilation in 3018 (70%) eyes, of which 738 (24%) were successfully epilated (no lashes touching globe). Epilation was performed frequently (at least monthly in 3311 [76.8%] eyes), by someone other than the patient (92.8%), and using locally made forceps (88.9%). Controlling for age and degree of entropion, successful epilation was associated with less corneal opacity (odds ratio [OR], 0.61; 95% confidence interval [CI]. 0.43-0.88; P = 0.007). The association was only significant in patients with severe entropion (OR, 0.07; 95% CI, 0.02-0.25; P<0.005)., Conclusions: We found an association between successful epilation and less central corneal opacity. This indicates the importance of preventing eyelashes from touching the cornea, particularly in individuals with severe entropion. This is a cross-sectional study; therefore, a causative relationship cannot be concluded. However, the results suggest that among patients who decline or are unable to access surgery, and perhaps in minor TT where the management remains controversial, the provision of high-quality forceps and epilation training may be beneficial., Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article., (Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
38. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
- Author
-
Maeda-Chubachi T, Chi-Burris K, Simons BD, Freedman SF, Khaw PT, Wirostko B, and Yan E
- Subjects
- Adolescent, Antihypertensive Agents adverse effects, Child, Child, Preschool, Double-Blind Method, Female, Glaucoma physiopathology, Humans, Hydrophthalmos physiopathology, Infant, Latanoprost, Male, Ophthalmic Solutions administration & dosage, Ophthalmic Solutions adverse effects, Prospective Studies, Prostaglandins F, Synthetic adverse effects, Time Factors, Timolol adverse effects, Tonometry, Ocular, Treatment Outcome, Antihypertensive Agents administration & dosage, Glaucoma drug therapy, Hydrophthalmos drug therapy, Intraocular Pressure drug effects, Prostaglandins F, Synthetic administration & dosage, Timolol administration & dosage
- Abstract
Objective: To compare the efficacy and safety of latanoprost versus timolol in pediatric patients with glaucoma., Design: Prospective, randomized, double-masked, 12-week, multicenter study., Participants: Individuals aged ≤18 years with glaucoma., Methods: Stratified by age, diagnosis, and intraocular pressure (IOP) level, subjects were randomized (1:1) to latanoprost vehicle at 8 am and latanoprost 0.005% at 8 pm or timolol 0.5% (0.25% for those aged <3 years) twice daily (8 am, 8 pm). At baseline and weeks 1, 4, and 12, IOP and ocular safety were assessed and adverse events were recorded. Therapy was switched to open-label latanoprost pm and timolol am and pm for uncontrolled IOP., Main Outcome Measures: Mean IOP reduction from baseline to week 12. Latanoprost was considered noninferior to timolol if the lower limit of the 95% confidence interval (CI) of the difference was >-3 mmHg. A proportion of responders (subjects with ≥15% IOP reduction at weeks 4 and 12) were evaluated. Analyses were performed in diagnosis subgroups: primary congenital glaucoma (PCG) and non-PCG., Results: In total, 137 subjects were treated (safety population; 12-18 years, n=48; 3-<12 years, n=55; 0-<3 years, n=34). Mean age was 8.8±5.5 years, and mean baseline IOP was 27.7±6.17 mmHg; 125 subjects completed the study, and 107 subjects were in the per protocol population. Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21). Responder rates were 60% for latanoprost and 52% for timolol (P=0.33). Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively. Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group. Both therapies were well tolerated., Conclusions: Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG. Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial., Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references., (Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
39. CYP1B1-related anterior segment developmental anomalies novel mutations for infantile glaucoma and von Hippel's ulcer revisited.
- Author
-
Kelberman D, Islam L, Jacques TS, Russell-Eggitt I, Bitner-Glindzicz M, Khaw PT, Nischal KK, and Sowden JC
- Subjects
- Anterior Eye Segment abnormalities, Anterior Eye Segment pathology, Anterior Eye Segment surgery, Consanguinity, Corneal Opacity pathology, Corneal Opacity surgery, Cytochrome P-450 CYP1B1, DNA Mutational Analysis, Eye Abnormalities pathology, Eye Abnormalities surgery, Female, Genotype, Humans, Hydrophthalmos pathology, Hydrophthalmos therapy, Infant, Intraocular Pressure, Keratoplasty, Penetrating, Male, Microscopy, Acoustic, Pedigree, Prevalence, Retrospective Studies, Reverse Transcriptase Polymerase Chain Reaction, Aryl Hydrocarbon Hydroxylases genetics, Corneal Opacity genetics, Eye Abnormalities genetics, Hydrophthalmos genetics, Mutation
- Abstract
Purpose: To determine the prevalence of CYP1B1 mutations in a cohort of patients with congenital corneal opacification (CCO), infantile glaucoma, or both and to describe a developmental CCO associated with CYP1B1 mutation that may explain von Hippel's original description of an internal ulcer., Design: Retrospective genotyping of a cohort of patients with infantile glaucoma and CCO., Participants: Thirty-three patients with CCO, infantile glaucoma, or both., Methods: All patients underwent a full clinical evaluation with or without examination under anesthetic including anterior segment photography, ultrasound biomicroscopy (for CCO patients; n = 22), and histopathologic analysis in patients in whom penetrating keratoplasty (PK) was performed (n = 10). Patient DNA and DNA from 50 normal control individuals who had undergone a full ophthalmologic examination were screened for CYP1B1 mutations., Main Outcome Measures: Classification of the developmental corneal opacity phenotype in infantile glaucoma patients with CYP1B1 mutations., Results: Nine distinct pathogenic recessive CYP1B1 mutations were found in 11 patients from 6 unrelated families, including 1 patient with an entire deletion of the CYP1B1 gene. Two of these patients, including the patient with the deletion, had isolated infantile congenital glaucoma with no other abnormalities. No CYP1B1 mutations were found in another 13 patients (7 of whom underwent PK in at least 1 eye) who had CCO with iridocorneal or keratolenticular adhesions (Peters' anomaly types I and II, respectively). Eight further children with CYP1B1 mutations who had CCO from birth and glaucoma underwent successful glaucoma treatment but had persistent diffuse CCO without iridocorneal or keratolenticular adhesions. Three of these underwent bilateral PK, and the histologic results were not consistent with any hitherto recognized congenital corneal dystrophy and showed abnormalities of the central corneal endothelium., Conclusions: Both severe CCO and isolated infantile glaucoma are associated with CYP1B1 mutations. The severe CCO phenotype reported herein often requires PK and has typical histopathologic changes. The mutations associated with this phenotype have not been reported previously. This phenotype may explain the patient described by Von Hippel in 1897., (Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
40. Outcomes of goniotomy for primary congenital glaucoma in East Africa.
- Author
-
Bowman RJ, Dickerson M, Mwende J, and Khaw PT
- Subjects
- Adolescent, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Hydrophthalmos epidemiology, Hydrophthalmos physiopathology, Infant, Intraocular Pressure physiology, Male, Reoperation, Retrospective Studies, Risk Factors, Tanzania epidemiology, Treatment Outcome, Visual Acuity physiology, Hydrophthalmos surgery, Trabeculectomy
- Abstract
Objective: To evaluate the effectiveness of goniotomy to treat primary congenital glaucoma in an east African population., Design: A retrospective series using case records. For patients who underwent goniotomies in both eyes, only the first was analyzed., Participants: Forty-seven children undergoing goniotomy (47/80 operated eyes analyzed). Thirty-six children (77%) were male. Mean age was 19 months (range 1-204 months, standard deviation [SD] = 35)., Intervention: First goniotomy was performed from the temporal side. Repeat surgery, if necessary, was performed via nasal side approach and 100% ethanol-soaked cotton-tipped swabs were used to clear the corneal epithelium when necessary for angle visualization., Main Outcome Measures: Postoperative intraocular pressure (IOP) <21 mmHg was considered success. Potential risk factors for failure were analyzed. Quantitative visual acuities were measured with Cardiff acuity cards and Lea tests in older children., Results: A total of 36 of 47 children (77%) returned for follow-up. Mean follow-up interval was 12 months (range, 1-62 months; SD = 15). A total of 28 of 47 children (60%) had >3 months of follow-up, and 11 children had >1 year of follow-up. A total of 12 of 47 eyes (26%) required repeat goniotomy. Three of these required further trabeculectomy with mitomycin C, 1 of which required eventual enucleation after failure to control IOP, enlargement, and pain. A total of 11 of 28 children (39%) with >3 months follow-up required repeat surgery. A total of 24 of 28 children (86%) with follow-up intervals of at least 3 months achieved postoperative IOPs of <21 mmHg. Mean IOPs decreased (t = 6.1, P < 0.0005) from 23.4 mmHg (SD = 5.3 mmHg) to 14.4 mmHg (SD = 7.6 mmHg). Only 1 predictor of failure to achieve successful control of IOP was identified: female gender (relative risk = 5.3, 95% confidence interval, 1.1-26.3). Corneas were clear in 4 of 47 eyes (8.5%) preoperatively and 32 of 41 eyes (78%) postoperatively. Of 25 children with preoperative and postoperative acuities measured, 22 (88%) recorded improvement., Conclusions: Preliminary results of goniotomy in an African population with advanced disease and late presentation are reasonably encouraging. Overall results are comparable with historical drainage procedures, with the advantage of preserving conjunctiva. Further studies are justified., (Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
41. The effect of MMP inhibitor GM6001 on early fibroblast-mediated collagen matrix contraction is correlated to a decrease in cell protrusive activity.
- Author
-
Martin-Martin B, Tovell V, Dahlmann-Noor AH, Khaw PT, and Bailly M
- Subjects
- Animals, Cell Line, Fibroblasts metabolism, Humans, Matrix Metalloproteinase Inhibitors, Matrix Metalloproteinases metabolism, Mice, Microscopy, Confocal, Staining and Labeling, Wound Healing physiology, Cell Movement physiology, Cell Shape physiology, Collagen metabolism, Dipeptides pharmacology, Extracellular Matrix metabolism, Fibroblasts drug effects, Fibroblasts physiology
- Abstract
Although fibroblasts play an essential part during the wound healing response, the mechanisms by which they mediate tissue remodelling and contraction are still unclear. Using live cell and matrix imaging within 3D free-floating fibroblast-populated collagen lattices as a model for tissue contraction, we compared the behaviour of a range of fibroblasts with low and high contraction abilities and analysed the effect of the broad spectrum MMP-inhibitor GM6001 on cell behaviour and matrix contraction. We identified two mechanisms underlying matrix contraction, one via direct cell-mediated contractile activity, the second through matrix degradation. These appear to be linked to cell morphology and regulated by the collagen concentration within the matrix. Cells with a rounded morphology proliferated in the matrix but did not remodel it efficiently, resulting in a poor ability to contract matrices. Cells with an elongated morphology showed higher levels of protrusive activity, leading to efficient matrix remodelling and contraction. GM6001 inhibited week-long matrix contraction to various extents with the different cell lines. However, quantitative analysis of the cell protrusive activity showed that GM6001 consistently decreased cell dynamics in 3D by about 20%, and this was correlated with a significant reduction in early matrix contraction. Overall our results suggest that although fibroblast-mediated matrix contraction depends on both cell dynamics and MMP-mediated matrix degradation, the efficiency of GM6001 treatment in preventing contraction might be linked to a direct effect on cell dynamics., (Copyright © 2010 Elsevier GmbH. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
42. Tear cytokine profile in medicated glaucoma patients: effect of monocyte chemoattractant protein 1 on early posttrabeculectomy outcome.
- Author
-
Chong RS, Jiang YZ, Boey PY, Yu SJ, Htoon HM, Aung T, Khaw PT, and Wong TT
- Subjects
- Aged, Aged, 80 and over, Case-Control Studies, Cytokines metabolism, Female, Follow-Up Studies, Glaucoma drug therapy, Glaucoma surgery, Humans, Intraocular Pressure drug effects, Male, Middle Aged, Postoperative Period, Prospective Studies, Treatment Outcome, Antihypertensive Agents administration & dosage, Chemokine CCL2 metabolism, Eye Proteins metabolism, Glaucoma metabolism, Tears metabolism, Trabeculectomy
- Abstract
Purpose: To determine the tear cytokine profile from medicated glaucoma patients scheduled for trabeculectomy and to establish whether a specifically elevated cytokine level is related to early postoperative scarring., Design: Prospective case-control study., Participants: Sixty-one patients treated with topical antiglaucoma medications and 29 normal subjects with no prior topical treatment were recruited for the study., Methods: Schirmer strips were used to collect tear samples. A multiplex bead assay was used to quantify the presence of proinflammatory cytokines in the tears. The patients were followed up for 6 months after surgery to determine whether any postoperative intervention to maintain filtering bleb function was required., Main Outcome Measures: The level of cytokines in tear specimens from medicated glaucoma patients was the main outcome measure for the study. The need for postoperative bleb needling within 6 months was a secondary outcome measure., Results: Of the 17 cytokines assayed, only monocyte chemoattractant protein 1 (MCP-1) was elevated significantly in the medicated eyes compared with the unmedicated eyes (P < 0.0004). At 6 months after surgery, 18 (30%) of the 61 eyes required postoperative intervention. A much higher MCP-1 level was detected in these eyes compared with the remaining 43 that did not require intervention (P < 0.0001). The duration of use of topical medication correlated with increasing levels of MCP-1, although the types of glaucoma medication and the number of bottles of medications did not have any significant relationship with the level of MCP-1., Conclusions: In tears from topically medicated glaucoma eyes in an Asian population, MCP-1 was found to be the predominant cytokine elevated. Eyes with a propensity to scar in the early postoperative period have a significantly raised level of MCP-1., Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references., (Copyright © 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
43. Current approaches and future prospects for stem cell rescue and regeneration of the retina and optic nerve.
- Author
-
Dahlmann-Noor A, Vijay S, Jayaram H, Limb A, and Khaw PT
- Subjects
- Animals, Glaucoma physiopathology, Glaucoma therapy, Humans, Retinal Diseases physiopathology, Retinal Diseases therapy, Retinal Ganglion Cells cytology, Nerve Regeneration physiology, Optic Nerve physiology, Retina physiology, Stem Cell Transplantation, Stem Cells physiology
- Abstract
The 3 most common causes of visual impairment and legal blindness in developed countries (age-related macular degeneration, glaucoma, and diabetic retinopathy) share 1 end point: the loss of neural cells of the eye. Although recent treatment advances can slow down the progression of these conditions, many individuals still suffer irreversible loss of vision. Research is aimed at developing new treatment strategies to rescue damaged photoreceptors and retinal ganglion cells (RGC) and to replace lost cells by transplant. The neuroprotective and regenerative potential of stem and progenitor cells from a variety of sources has been explored in models of retinal disease and ganglion cell loss. Continuous intraocular delivery of neurotrophic factors via stem cells (SC) slows down photoreceptor cells and RGC loss in experimental models. Following intraocular transplantation, SC are capable of expressing proteins and of developing a morphology characteristic of photoreceptors or RGC. Recently, recovery of vision has been achieved for the first time in a rodent model of retinal dystrophy, using embryonic SC differentiated into photoreceptors prior to transplant. This indicates that clinically significant synapse formation and acquisition of the functional properties of retinal neurons, and restoration of vision, are distinct future possibilities.
- Published
- 2010
- Full Text
- View/download PDF
44. The singapore 5-Fluorouracil trabeculectomy study: effects on intraocular pressure control and disease progression at 3 years.
- Author
-
Wong TT, Khaw PT, Aung T, Foster PJ, Htoon HM, Oen FT, Gazzard G, Husain R, Devereux JG, Minassian D, Tan SB, Chew PT, and Seah SK
- Subjects
- Adult, Aged, Combined Modality Therapy, Disease Progression, Double-Blind Method, Female, Follow-Up Studies, Glaucoma, Angle-Closure drug therapy, Glaucoma, Angle-Closure physiopathology, Glaucoma, Angle-Closure surgery, Glaucoma, Open-Angle drug therapy, Glaucoma, Open-Angle physiopathology, Glaucoma, Open-Angle surgery, Humans, Intraoperative Care, Male, Middle Aged, Optic Disk pathology, Prospective Studies, Risk, Singapore, Visual Fields, Antimetabolites, Antineoplastic administration & dosage, Fluorouracil administration & dosage, Glaucoma, Angle-Closure therapy, Glaucoma, Open-Angle therapy, Intraocular Pressure physiology, Trabeculectomy
- Abstract
Purpose: To report 3-year results of a randomized, controlled trial comparing the use of a single application of 5-fluorouracil (5-FU) with placebo in trabeculectomy surgery., Design: Prospective, randomized, double-blinded treatment trial., Participants: Two hundred forty-three Asian patients with primary open-angle or primary angle-closure glaucoma undergoing primary trabeculectomy., Methods: One eye of each patient was randomized to receive either intraoperative 5-FU or normal saline (placebo) during trabeculectomy., Main Outcome Measures: Primary outcome measure was the level of intraocular pressure (IOP). Secondary outcomes were progression of visual field loss, rates of adverse events, and interventions after surgery., Results: Of the 288 eligible patients, 243 were enrolled and 228 completed 3 years follow-up; 120 patients received 5-FU and 123 received placebo. Trial failure, according to predefined IOP criteria, was lower in the 5-FU group compared with the placebo group, although the difference was only significant with a failure criterion of IOP >17 mmHg (P = 0.0154). There was no significant difference in progression of optic disc and/or visual field loss over 36 months between 5-FU and placebo (relative risk [RR], 0.67; 95% confidence interval [CI], 0.34-1.31; P = 0.239). Uveitis occurred more often in the 5-FU-treated group (14/115 [12%] vs 5/120 [4%]; P = 0.032)., Conclusions: This is the first masked, prospective, randomized trial reporting the effect of adjunctive 5-FU in trabeculectomy surgery in an East Asian population. The trial shows that an increased success rate can be achieved for several years after a single intraoperative treatment with 5-FU. We conclude that 5-FU is relatively safe and can be routinely used in low-risk East Asian patients., Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article.
- Published
- 2009
- Full Text
- View/download PDF
45. Matrix metalloproteinase inhibition reduces contraction by dupuytren fibroblasts.
- Author
-
Townley WA, Cambrey AD, Khaw PT, and Grobbelaar AO
- Subjects
- Aged, Cell Culture Techniques, Cell Proliferation drug effects, Collagen, Enzyme-Linked Immunosorbent Assay, Female, Fibroblasts metabolism, Humans, Hydroxamic Acids, Male, Middle Aged, Up-Regulation, Dupuytren Contracture pathology, Fibroblasts drug effects, Indoles pharmacology, Matrix Metalloproteinase Inhibitors
- Abstract
Purpose: Dupuytren's disease is a common fibroproliferative condition of the hand characterized by fibrotic lesions (nodules and cords), leading to disability through progressive digital contracture. Although the etiology of the disease is poorly understood, recent evidence suggests that abnormal matrix metalloproteinase (MMP) activity may play a role in cell-mediated collagen contraction and tissue scarring. The aim of this study was to investigate the efficacy of ilomastat, a broad-spectrum MMP inhibitor, in an in vitro model of Dupuytren fibroblast-mediated contraction., Methods: Nodule-derived and cord-derived fibroblasts were isolated from Dupuytren patients; carpal ligament-derived fibroblasts acted as control. Stress-release fibroblast-populated collagen lattices (FPCLs) were used as a model of contraction. FPCLs were allowed to develop mechanical stress (48 hours) during treatment with ilomastat (0-100 micromol/L), released, and allowed to contract over a 48-hour period. Contraction was estimated by measuring lattice area compared with untreated cells or treatment with a control peptide. MMP-1, MMP-2, and MT1-MMP levels were assessed by zymography, Western blotting, and enzyme-linked immunosorbent assay., Results: Nodule-derived fibroblasts contracted lattices (69% +/- 2) to a greater extent than did cord-derived (55% +/- 3) or carpal ligament-derived (55% +/- 1) fibroblasts. Exposure to ilomastat led to significant inhibition of lattice contraction by all fibroblasts, although a reduction in lattice contraction by nodule-derived fibroblasts was most prominent (84% +/- 8). In addition, treatment with ilomastat led to a concomitant suppression of MMP-1 and MMP-2 activity, whereas MT1-MMP activity was found to be upregulated., Conclusions: Our results demonstrate that inhibition of MMP activity results in a reduction in extracellular matrix contraction by Dupuytren fibroblasts and suggest that MMP activity may be a critical target in preventing recurrent contracture caused by this disease.
- Published
- 2008
- Full Text
- View/download PDF
46. Angle-closure.
- Author
-
Low S, Harsum S, Chang L, Foster PJ, and Khaw PT
- Subjects
- Acute Disease, Anterior Eye Segment diagnostic imaging, Anterior Eye Segment drug effects, Antihypertensive Agents therapeutic use, Child, Preschool, Cyclopentolate adverse effects, Drug Therapy, Combination, Female, Glaucoma, Angle-Closure drug therapy, Humans, Intraocular Pressure drug effects, Microscopy, Acoustic, Phenylephrine adverse effects, Pupil drug effects, Tonometry, Ocular, Glaucoma, Angle-Closure chemically induced, Mydriatics adverse effects
- Published
- 2008
- Full Text
- View/download PDF
47. Modulation of wound healing during and after glaucoma surgery.
- Author
-
Georgoulas S, Dahlmann-Noor A, Brocchini S, and Khaw PT
- Subjects
- Antibiotics, Antineoplastic pharmacology, Cicatrix drug therapy, Cicatrix prevention & control, Dendrimers chemistry, Dendrimers therapeutic use, Fibroblasts drug effects, Glaucoma drug therapy, Humans, Immunologic Factors chemistry, Immunologic Factors therapeutic use, Inflammation drug therapy, Intraocular Pressure, Mitomycin pharmacology, Neovascularization, Pathologic drug therapy, Regeneration, Filtering Surgery adverse effects, Filtering Surgery methods, Glaucoma surgery, Trabeculectomy adverse effects, Trabeculectomy methods, Wound Healing
- Abstract
Following all types of glaucoma filtration surgery (GFS), scarring still poses the major threat to long-term success. The healing and scarring determine the percentage of patients achieving low final intraocular pressures (IOPs) that are associated with virtually no glaucoma progression. The use of antifibrotic agents to inhibit scarring of trabeculectomy blebs is now a well-established clinical practice. Unfortunately, severe complications such as leakage, infection, hypotony, and endophthalmitis with complete loss of vision may occur. In addition, surgery still fails in some individuals despite maximal doses of current antifibrotics. Better therapeutic agents are needed. Many promising new agents are being evaluated clinically and in vitro. In this chapter, we will discuss our current understanding of the wound healing process after glaucoma surgery and promising new treatment modalities.
- Published
- 2008
- Full Text
- View/download PDF
48. A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy.
- Author
-
Khaw P, Grehn F, Holló G, Overton B, Wilson R, Vogel R, and Smith Z
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Chronic Disease, Combined Modality Therapy, Conjunctiva pathology, Double-Blind Method, Exfoliation Syndrome surgery, Female, Fibrosis prevention & control, Humans, Intraocular Pressure, Male, Middle Aged, Prospective Studies, Tonometry, Ocular, Transforming Growth Factor beta2 immunology, Treatment Outcome, Antibodies, Monoclonal administration & dosage, Conjunctiva drug effects, Glaucoma, Angle-Closure surgery, Glaucoma, Open-Angle surgery, Trabeculectomy
- Abstract
Objective: To evaluate CAT-152 (lerdelimumab), a monoclonal antibody to transforming growth factor-beta2 (TGF-beta2), in preventing the progression of fibrosis in patients undergoing first-time trabeculectomy for primary open-angle (POAG) or chronic angle-closure glaucoma (CACG)., Design: Randomized, double-masked, multicenter, placebo-controlled trial., Participants: Individuals with a diagnosis of POAG, CACG, pseudoexfoliative glaucoma (PEXG), or pigmentary glaucoma (PG), with a recorded intraocular pressure (IOP) of more than 21 mmHg, visual field or optic disc changes characteristic of glaucoma, and taking the maximum tolerated dose of medication., Intervention: Patients received unilateral trabeculectomy with either 4 subconjunctival injections of CAT-152 (100 microg in 100 microl phosphate buffer) or 4 placebo injections, administered immediately before and on completion of trabeculectomy, and on the first day and at 1 week after surgery. Patients were followed up for 12 months after surgery., Main Outcome Measures: The primary outcome measure was treatment success in the study eye (unmedicated IOP of 6-16 mmHg inclusive), at the 6- and 12-month follow-up. Secondary outcome measures were the incidence of postoperative intervention with 5-fluorouracil (5-FU); incidence of surgical failure; time to surgical failure; and incidence of vascularity, microcysts, and encapsulation or demarcation of the bleb site., Results: Of the 388 patients evaluated in the trial, 81% (n = 274) had either POAG or CACG, combined into a single set (POAG/CACG) analyzed by intent-to-treat (ITT) criteria. Separate ITT analyses were carried out for all participants (+PEXG/PG group), with similar results. The treatment success rate was 60% in the CAT-152 group and 68% in the placebo group (P = 0.23). No statistically significant differences emerged in the secondary end points. Patients requiring 5-FU for postsurgical management were more likely to be treatment failures (P = 0.0003). Patients with a primary diagnosis of PG (n = 49) had a higher success rate than those with other diagnoses (P = 0.0077). Administration of CAT-152 was not associated with an increased incidence of adverse events. The immunogenicity of CAT-152 was very low., Conclusions: At the dose level and regimen studied, there was no difference between CAT-152 and placebo in preventing the failure of primary trabeculectomy. The safety profile of CAT-152 was similar to that of placebo.
- Published
- 2007
- Full Text
- View/download PDF
49. Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152.
- Author
-
Grehn F, Holló G, Khaw P, Overton B, Wilson R, Vogel R, and Smith Z
- Subjects
- Aged, Antibodies, Monoclonal, Humanized, Chronic Disease, Clinical Trials, Phase III as Topic, Conjunctiva pathology, Exfoliation Syndrome surgery, Female, Fibrosis prevention & control, Humans, Intraocular Pressure, Male, Middle Aged, Retrospective Studies, Risk Factors, Transforming Growth Factor beta2 immunology, Treatment Outcome, Antibodies, Monoclonal administration & dosage, Conjunctiva drug effects, Glaucoma, Angle-Closure surgery, Glaucoma, Open-Angle surgery, Trabeculectomy
- Abstract
Purpose: To determine the factors affecting trabeculectomy success., Design: Retrospective analysis of 2 randomized controlled trials comparing an antibody against transforming growth factor beta2 (TGF-beta2) with vehicle (placebo) for prevention of fibrosis after trabeculectomy, in which there was no significant difference between the treatment groups., Participants: Data were from patients (n = 726) with a diagnosis of primary open-angle glaucoma, chronic angle-closure glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma (PG) who had an intraocular pressure (IOP) > 21 mmHg and visual field or optic disc changes characteristic of glaucoma and were taking the maximum tolerated dose of medication before trabeculectomy., Methods: Patients had trabeculectomy and 4 subconjunctival injections of a human monoclonal antibody to TGF-beta2 (CAT-152) or a placebo. The definition of trabeculectomy success in the protocols was an IOP between 6 and 16 mmHg inclusive at months 6 and 12. Analyses of success used factors identified by ophthalmic experts., Main Outcomes Measures: Covariates analyzed included patient age, black race, gender, time since diagnosis, primary diagnosis, country, diabetes, mean defect, cup-to-disc (C/D) ratio, suture type, anesthetic, flap type, IOP at listing for surgery, suture release/lysis, needling, reformed anterior chamber, wound leak, severe bleb vascularity, and bleb microcysts., Results: A stepwise logistic regression model found the following predictors of treatment success: PG (odds ratio [OR], 4.11; 95% confidence interval [CI], 1.41-11.99), high C/D ratio (OR, 2.84; 95% CI, 1.15-6.99), and use of a corneal traction suture (OR, 1.67; 95% CI, 1.09-2.56). A negative relationship was found for black race (OR, 0.28; 95% CI, 0.13-0.62); treatment in France (OR, 0.35; 95% CI, 0.17-0.70), Sweden (OR, 0.17; 95% CI, 0.05-0.58), Spain (OR, 0.37; 95% CI, 0.21-0.68), Poland (OR, 0.53; 95% CI, 0.32-0.88), or Hungary (OR, 0.14; 95% CI, 0.06-0.34); and suture release/lysis (OR, 0.34; 95% CI, 0.22-0.53). The effect of needling was marginally statistically significant (OR, 0.56; 95% CI, 0.31-1.01)., Conclusions: Successful trabeculectomy outcome was associated with PG, higher C/D ratio, and corneal traction suturing. Factors associated with surgical failure were black race and suture release/lysis. Intercountry differences also were observed.
- Published
- 2007
- Full Text
- View/download PDF
50. Laser peripheral iridotomy in eyes with narrow drainage angles: ultrasound biomicroscopy outcomes. The Liwan Eye Study.
- Author
-
He M, Friedman DS, Ge J, Huang W, Jin C, Cai X, Khaw PT, and Foster PJ
- Subjects
- Aged, Asian People ethnology, China epidemiology, Ciliary Body diagnostic imaging, Female, Glaucoma, Angle-Closure diagnostic imaging, Glaucoma, Angle-Closure ethnology, Gonioscopy, Humans, Intraocular Pressure, Iris diagnostic imaging, Male, Middle Aged, Prospective Studies, Treatment Outcome, Anterior Eye Segment diagnostic imaging, Glaucoma, Angle-Closure surgery, Iridectomy methods, Iris surgery, Laser Therapy methods, Microscopy, Acoustic
- Abstract
Purpose: To assess the short-term effect of laser peripheral iridotomy (LPI) on anterior segment anatomy in angle-closure suspects using ultrasound biomicroscopy (UBM)., Design: Prospective intervention study., Participants: Persons identified as angle-closure suspects aged 50-79 years from a population-based survey in Guangzhou, China., Intervention: Laser peripheral iridotomy was performed on 1 randomly selected eye. Ultrasound biomicroscopy examination was carried out before and 2 weeks after the intervention., Main Outcome Measures: Proportion of eyes with iridotrabecular contact (ITC), as well as changes in UBM parameters including angle opening distance (AOD), iris thickness (IT), iris curvature, iris ciliary process distance, trabecular-ciliary process distance (TCPD), and scleral spur to iris insertion distance (SS-IR)., Results: A total of 72 of 101 eligible subjects participated in the study. The proportion of people with UBM-identified ITC in > or =1 quadrant dropped from 95% (68/72) before to 59% (42/72) after LPI. After LPI, the mean AOD at 250 microns increased from 0.064 mm (standard deviation [SD], 0.052) to 0.085 (0.052) mm (P<0.001); angle recess area increased from 0.040 (0.030) to 0.070 (0.036) mm2 (P<0.0001); TCPD increased from 0.537 to 0.561 mm (P = 0.001); IT at 750 microns increased from 0.440 to 0.459 mm (P = 0.094), and IT at 1000 microns increased from 0.471 to 0.488 mm (P = 0.0001). Eyes whose angles remained closed after LPI (pigmented trabecular meshwork not visible in > or =3 quadrants) tended to have shallower AOD both at 250 (0.071 vs. 0.049 mm; P = 0.09) and 500 microns (0.108 vs. 0.052 mm; P = 0.001), a thicker iris (IT at 750 microns, 0.447 vs. 0.415 mm; P = 0.041), a more anterior positioned ciliary body (TCPD, 0.514 vs. 0.562 mm; P = 0.03), and a statistically nonsignificant more anterior iris insertion (SS-IR: 0.085 vs. 0.125 mm; P = 0.061), before LPI., Conclusions: Laser peripheral iridotomy results in a significant increase in the angle width in Chinese people with narrow angles. However, some iridotrabecular contact was found in 59% of eyes with a patent iridotomy. This was associated with smaller anterior chamber angle dimensions and a thicker iris, both of which may play a causative role in maintaining angle closure after LPI.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.